{"sentence": "Among the anti-herpesvirus agents , aciclovir , valaciclovir , penciclovir , famciclovir , idoxuridine , trifluridine and brivudin are used in the treatment of herpes simplex virus and varicella-zoster virus infections , and ganciclovir , foscarnet , cidofovir , fomivirsen and maribavir ( the latter in the developmental stage ) are used in the treatment of cytomegalovirus infections .", "spans": [{"span_id": 0, "text": "aciclovir", "start": 36, "end": 45, "token_start": 5, "token_end": 5}, {"span_id": 1, "text": "valaciclovir", "start": 48, "end": 60, "token_start": 7, "token_end": 7}, {"span_id": 2, "text": "penciclovir", "start": 63, "end": 74, "token_start": 9, "token_end": 9}, {"span_id": 3, "text": "famciclovir", "start": 77, "end": 88, "token_start": 11, "token_end": 11}, {"span_id": 4, "text": "idoxuridine", "start": 91, "end": 102, "token_start": 13, "token_end": 13}, {"span_id": 5, "text": "trifluridine", "start": 105, "end": 117, "token_start": 15, "token_end": 15}, {"span_id": 6, "text": "ganciclovir", "start": 225, "end": 236, "token_start": 33, "token_end": 33}, {"span_id": 7, "text": "foscarnet", "start": 239, "end": 248, "token_start": 35, "token_end": 35}, {"span_id": 8, "text": "cidofovir", "start": 251, "end": 260, "token_start": 37, "token_end": 37}], "rels": [], "paragraph": "Antiviral drugs: current state of the art. The chemotherapy of virus infections has definitely come of age. There are now 15 antiviral agents that have been formally licensed for the treatment of human immunodeficiency virus infections (zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, nevirapine, delavirdine, efavirenz, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir) and several others, such as tenofovir disoproxil, emtricitabine, capravirine, emivirine, T-20 (pentafuside) and AMD3100 (bicyclam) are under clinical development. Lamivudine has been approved, and several other compounds (such as adefovir dipivoxil, emtricitabine and entecavir) are under clinical development, for the treatment of hepatitis B virus infections. Among the anti-herpesvirus agents , aciclovir , valaciclovir , penciclovir , famciclovir , idoxuridine , trifluridine and brivudin are used in the treatment of herpes simplex virus and varicella-zoster virus infections , and ganciclovir , foscarnet , cidofovir , fomivirsen and maribavir ( the latter in the developmental stage ) are used in the treatment of cytomegalovirus infections . Following amantadine and rimantadine, the neuraminidase inhibitors, zanamivir and oseltamivir, have now become available for the therapy and prophylaxis of influenza virus infections, and so is ribavirin for the treatment of respiratory syncytial virus infections and the combination of ribavirin with interferon-alpha for the treatment of hepatitis C virus infections."}
{"sentence": "The present study examined the efficacy of single and combined treatment with an anticholinesterase , tetrahydroaminoacridine ( i.p . ) , and a glycine-B site partial agonist , D-cycloserine ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi .", "spans": [{"span_id": 0, "text": "D-cycloserine", "start": 177, "end": 190, "token_start": 28, "token_end": 28}, {"span_id": 1, "text": "lidocaine", "start": 370, "end": 379, "token_start": 60, "token_end": 60}], "rels": [], "paragraph": "Tetrahydroaminoacridine and D-cycloserine fail to alleviate the water maze spatial navigation defect induced by hippocampal inactivation.  The present study examined the efficacy of single and combined treatment with an anticholinesterase , tetrahydroaminoacridine ( i.p . ) , and a glycine-B site partial agonist , D-cycloserine ( i.p . ; a positive allosteric modulator of NMDA receptors ) , in alleviating the deficit in water maze spatial navigation induced by electrolytic lesion of the medial septum or lidocaine infusion into the dorsal hippocampi . In medial septum-lesioned rats, a combination of tetrahydroaminoacridine 3 mg kg(-1) and D-cycloserine 10 mg kg(-1) facilitated acquisition of the water maze test more effectively than either of the drugs alone. Single or combined treatment with tetrahydroaminoacridine 3 mg kg(-1) and D-cycloserine 10 mg kg(-1) had no effect on the water maze deficit induced by hippocampal lidocaine infusion. These results suggest that combined treatment with tetrahydroaminoacridine and D-cycloserine can effectively stimulate water maze spatial navigation, and that functioning of the hippocampus is a prerequisite for this effect."}
{"sentence": "He was initially treated with combination chemotherapy regimen of vincristine , actinomycin-D and cyclophosphamide ( VAC therapy ) .", "spans": [{"span_id": 0, "text": "vincristine", "start": 66, "end": 77, "token_start": 9, "token_end": 9}, {"span_id": 1, "text": "cyclophosphamide", "start": 98, "end": 114, "token_start": 13, "token_end": 13}, {"span_id": 2, "text": "actinomycin-D", "start": 80, "end": 93, "token_start": 11, "token_end": 11}], "rels": [{"class": "COMB", "spans": [0, 1, 2]}], "paragraph": "[Rhabdomyosarcoma of the bladder: a case report]. A 15-year-old man with the chief complaint of general fatigue was referred to our hospital on November 11, 1993. Bilateral percutaneous nephrostomy was performed for postrenal anuria. X-ray examinations revealed a huge intrapelvic tumor, and it was histopathologically diagnosed as rhabdomyosarcoma by transrectal needle biopsy. He was initially treated with combination chemotherapy regimen of vincristine , actinomycin-D and cyclophosphamide ( VAC therapy ) . Pelvic exenteration was performed on December 15, 1993. Histopathological findings were alveolar rhabdomyosarcoma with degenerative change and partial necrosis. After the operation, he was given two course of VAC therapy. In May, 1994, brain metastasis occurred, so 4 courses of VAC therapy were administered. For a very short period, neurological symptoms improved, but he died of pneumonia on November 15, 1994."}
{"sentence": "However , when a lung mass was noted two months later , he started to receive combination chemotherapy consisting of cyclophosphamide , adriamycin , vincristine , and prednisolone every three months .", "spans": [{"span_id": 0, "text": "cyclophosphamide", "start": 117, "end": 133, "token_start": 20, "token_end": 20}, {"span_id": 1, "text": "vincristine", "start": 149, "end": 160, "token_start": 24, "token_end": 24}, {"span_id": 2, "text": "prednisolone", "start": 167, "end": 179, "token_start": 27, "token_end": 27}, {"span_id": 3, "text": "adriamycin", "start": 136, "end": 146, "token_start": 22, "token_end": 22}], "rels": [{"class": "COMB", "spans": [0, 1, 2, 3]}], "paragraph": "[Lymphomatoid granulomatosis (LYG) occurring in a patient with follicular lymphoma during remission]. A 49 years-old man presented with dry cough, low grade fever, and abnormal shadow on a chest X-ray. He had suffered from follicular lymphoma of the liver 5 years previously. He received irradiation therapy in combination with chemotherapy for approximately three years and had been in complete remission. Physical and radiological examination revealed pleural effusion and softly dense masses in the right lung. The laboratory data were within normal limits. He was diagnosed as having lymphomatoid granulomatosis (LYG) by open lung biopsy. The lung lesion was mainly infiltrated with T cells. The patient received prednisolone and the lung lesions disappeared. However , when a lung mass was noted two months later , he started to receive combination chemotherapy consisting of cyclophosphamide , adriamycin , vincristine , and prednisolone every three months . He has not shown relapse of LYG so far. To investigate the association between the preceding follicular lymphoma and subsequent LYG at this time, DNA analysis using the PCR technique was carried out. The LYG lesion did not show a rearranged band for the JH probe, while the paraffin-embedded specimen of the preceding follicular lymphoma had shown rearranged band for the JH band. Southern blot analysis of the LYG lesion, showed no rearrangement for TCR beta, gamma or JH probe. These findings indicate that the LYG was different from the preceding follicular lymphoma in terms of origin. LYG is considered to be induced in the immunosuppressive state due to lymphoma."}
{"sentence": "Three patients treated initially with propranolol alone have required substitution of amiodarone due to refractory congestive heart failure .", "spans": [{"span_id": 0, "text": "propranolol", "start": 38, "end": 49, "token_start": 5, "token_end": 5}, {"span_id": 1, "text": "amiodarone", "start": 86, "end": 96, "token_start": 11, "token_end": 11}], "rels": [], "paragraph": "The role of beta-blockade therapy for ventricular tachycardia induced with isoproterenol: a prospective analysis. Isoproterenol is sometimes required for ventricular tachycardia (VT) induction. However, the role of beta-blockade for treatment of such VT has not been critically assessed. The use of beta-blockade was evaluated prospectively in 14 consecutive patients who required isoproterenol 2.4 +/- 1.3 (+/- S.D.) micrograms/min to induce sustained monomorphic VT (greater than 30 seconds, or requiring termination due to hemodynamic collapse) after a negative baseline study. The VT mechanisms were enhanced automaticity (group A, six patients), triggered automaticity (group B, three patients), and reentry (group C, five patients). Groups A and B had serial intravenous electropharmacologic tests with propranolol alone (0.2 mg/kg), verapamil alone (0.15 mg/kg), and propranolol plus verapamil, and group C had serial tests with propranolol alone, procainamide or quinidine (class Ia drug) alone, and propranolol plus a class Ia drug until VT could no longer be induced. All six patients in group A responded to propranolol alone. In group B, one patient responded to verapamil alone, and two patients responded to propranolol plus verapamil. In group C, three patients responded to propranolol alone, one patient responded to a class Ia drug alone, and one patient responded to propranolol plus a class Ia drug. During a follow-up of 7 to 37 (17.9 +/- 10.7) (+/- S.D.) months, VT has not recurred in any patient. Three patients treated initially with propranolol alone have required substitution of amiodarone due to refractory congestive heart failure . In patients requiring isoproterenol for VT induction, beta-blockade alone appears to be effective in preventing reinduction of VT caused by enhanced automaticity. A heterogeneous response occurs when the VT mechanisms are triggered automaticity or reentry."}
{"sentence": "We used MCF-7 and MDA-MB231 breast cancer cells incubated with Curcumin and Quercetin for 24h , in the absence and presence of Somatostatin , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways .", "spans": [{"span_id": 0, "text": "Curcumin", "start": 63, "end": 71, "token_start": 10, "token_end": 10}, {"span_id": 1, "text": "Somatostatin", "start": 127, "end": 139, "token_start": 22, "token_end": 22}, {"span_id": 2, "text": "Quercetin", "start": 76, "end": 85, "token_start": 12, "token_end": 12}], "rels": [{"class": "COMB", "spans": [0, 1, 2]}], "paragraph": "Effects of Somatostatin, Curcumin and Quercetin on the fatty acid profile of breast cancer cell membranes.  We used MCF-7 and MDA-MB231 breast cancer cells incubated with Curcumin and Quercetin for 24h , in the absence and presence of Somatostatin , at their EC50 concentrations , to evaluate membrane fatty acid-based functional lipidomics together with the follow-up of EGFR and MAPK signaling pathways . The two cell lines gave different membrane free fatty acid reorganization: in MCF-7 cells, the following changes observed: increase of omega-6 linoleic acid in the cells incubated with Somatostatin+Quercetin and Quercetin and decrease of omega-3 acids in the cells incubated with Somatostatin+Curcumin compared to Somatostatin, and significant increases of monounsaturated fatty acid (MUFA), mono-trans arachidonic acid levels and docosapentaenoic acid for the cells incubated with Somatostatin+Quercetin compared to the control cells. In MDA-MB231 cells, incubations with Curcumin, Quercetin and Somatostatin+Quercetin induced the most significant membrane remodeling with the increase of stearic acid, diminution of omega-6 linoleic, arachidonic acids and omega-3 (docosapentaenoic and docosahexaenoic acids). Distinct signaling pathway changes were found for these cell lines. In MCF-7 cells, separate or combined incubations with Somatostatin and Quercetin, significantly decreased EGFR and incubation with Curcumin decreased MAPK signaling. In MDA-MB231 cells, incubation with Curcumin decreased AKT1 and p-AKT1(Thr308) levels. Incubation with Curcumin and Quercetin decreased the EGFR levels."}
{"sentence": "Following corneal scrapings and culture , topical 0.5 % moxifloxacin and 0.5 % tobramycin were administered hourly .", "spans": [{"span_id": 0, "text": "moxifloxacin", "start": 56, "end": 68, "token_start": 9, "token_end": 9}, {"span_id": 1, "text": "tobramycin", "start": 79, "end": 89, "token_start": 13, "token_end": 13}], "rels": [{"class": "COMB", "spans": [0, 1]}], "paragraph": "A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin. A 70-year-old man with a long history of diabetes mellitus presented to our hospital (Department of Ophthalmology, Sahm Yook Medical Center, Seoul, Korea) complaining of severe ocular pain and visual disturbance in his left eye that had started three days prior to admission. A round 3.7 \u00d7 5.0 mm dense central stromal infiltrate with an overlying epithelial defect was noted on slit-lamp examination. Following corneal scrapings and culture , topical 0.5 % moxifloxacin and 0.5 % tobramycin were administered hourly . A few days later, Stenotrophomonas maltophilia was isolated in a bacterial culture from a corneal specimen. According to the results of susceptibility tests, topical 0.5% moxifloxacin was given every hour and 0.5% tobramycin was stopped. The patient's clinical features improved steadily with treatment. The corneal epithelium healed rapidly, and the infiltrate resolved within four weeks of the initiation of treatment. The patient's best corrected visual acuity improved from hand motion to 20 / 25."}
{"sentence": "Combination treatment with cetuximab and nystatin selectively increased cetuximab uptake by tumor tissues , translating into potentiated antitumor efficacy of cetuximab in vivo ( A431 and A549 tumors ) .", "spans": [{"span_id": 0, "text": "cetuximab", "start": 27, "end": 36, "token_start": 3, "token_end": 3}, {"span_id": 1, "text": "nystatin", "start": 41, "end": 49, "token_start": 5, "token_end": 5}, {"span_id": 2, "text": "cetuximab", "start": 72, "end": 81, "token_start": 8, "token_end": 8}, {"span_id": 3, "text": "cetuximab", "start": 159, "end": 168, "token_start": 20, "token_end": 20}], "rels": [{"class": "POS", "spans": [0, 1]}], "paragraph": "Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration. Cetuximab, a monoclonal antibody (mAb) targeting the epidermal growth factor receptor (EGFR), has been intensively investigated as a promising cancer treatment strategy. The specific mechanism of cetuximab endocytosis and its influence on cetuximab uptake, biodistribution and efficacy still remain elusive. Recently, statins have been reported to synergize with EGFR-targeting agents. Our prior work established that nystatin, a cholesterol-sequestering antifungal drug, facilitates endocytosis via the clathrin-dependent pathway. This study aimed to investigate whether nystatin regulates the uptake and efficacy of cetuximab and cetuximab-based antibody-drug conjugates (cetuximab-ADCs). In vitro and in vivo efficacies of nystatin on the uptake and activity of cetuximab/cetuximab-ADCs were studied in multiple human carcinoma cell lines and xenograft models, respectively. We identified that cholesterol sequestration by nystatin enhanced cetuximab internalization in EGFR-positive carcinoma cells by regulating EGFR trafficking/turnover and facilitating a switch from lipid rafts to clathrin-mediated endocytosis. Combination treatment with cetuximab and nystatin selectively increased cetuximab uptake by tumor tissues , translating into potentiated antitumor efficacy of cetuximab in vivo ( A431 and A549 tumors ) . Nystatin-enhanced internalization of cetuximab further improved the uptake and potency of cetuximab-doxorubicin and cetuximab-methotrexate conjugates in EGFR-positive cetuximab-resistant tumors. Combination therapy with nystatin plus either cetuximab or cetuximab-ADC further prolonged animal survival and significantly suppressed tumor growth, as compared with single-agent cetuximab or cetuximab-ADC. In summary, our results identify a novel mechanism whereby cholesterol sequestration enhances the uptake of EGFR-targeting mAb and ADCs, therefore providing preclinical proof-of-concept that combination with nystatin can potentiate the delivery and efficacy of these EGFR-targeted agents. "}
{"sentence": "The effects of combination therapy with chenodeoxycholic acid ( CDCA ) and simvastatin on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA .", "spans": [{"span_id": 0, "text": "chenodeoxycholic", "start": 40, "end": 56, "token_start": 6, "token_end": 6}, {"span_id": 1, "text": "simvastatin", "start": 75, "end": 86, "token_start": 12, "token_end": 12}], "rels": [{"class": "POS", "spans": [0, 1]}], "paragraph": "Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.  The effects of combination therapy with chenodeoxycholic acid ( CDCA ) and simvastatin on serum cholestanol , low-density lipoprotein ( LDL ) cholesterol , and lathosterol levels were investigated in seven adult patients with cerebrotendinous xanthomatosis ( CTX ) who were on long-term treatment with CDCA . The patients were treated with a combination of CDCA 750 mg daily and an increasing dose of simvastatin from 10 mg to 40 mg daily for a period of 6 months. We found a significant effect of this combination therapy compared with CDCA alone in terms of decreasing the serum cholestanol and LDL cholesterol levels, particularly with a daily dose of 40 mg simvastatin. The mean cholestanol level decreased from 9.27 micromol/L (baseline) to 6.69 micromol/L (40 mg simvastatin), while the mean LDL cholesterol level decreased from 5.08 mmol/L (baseline) to 3.04 mmol/L (40 mg simvastatin). No side effects were reported, and there were no effects on the clinical condition, cerebral magnetic resonance imaging (MRI), visual evoked potentials, and electroencephalographic features. We conclude that a combination of 750 mg CDCA and 40 mg simvastatin daily is effective to further reduce serum cholestanol, LDL cholesterol, and lathosterol in adult CTX patients treated with long-term CDCA. Whether this combination treatment will be effective for the long-term prevention of neurological deterioration and atherosclerosis remains to be established."}
{"sentence": "Paclitaxel ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) has been demonstrated to be highly effective in treating patients with advanced breast cancer , including those with anthracycline-resistant breast cancer , a fact that has led to efforts to combine paclitaxel and anthracyclines .", "spans": [{"span_id": 0, "text": "Paclitaxel", "start": 0, "end": 10, "token_start": 0, "token_end": 0}, {"span_id": 1, "text": "paclitaxel", "start": 268, "end": 278, "token_start": 43, "token_end": 43}, {"span_id": 2, "text": "anthracyclines", "start": 283, "end": 297, "token_start": 45, "token_end": 45}], "rels": [{"class": "COMB", "spans": [1, 2]}], "paragraph": "Paclitaxel and doxorubicin in metastatic breast cancer. For the past decades the anthracyclines have been regarded as among the most active drugs for the treatment of metastatic breast cancer. However, the 5-year survival rate in patients with stage IV breast cancer continues to be below 20%, and new active drugs and drug combinations clearly must be explored. Paclitaxel ( Taxol ; Bristol-Myers Squibb Company , Princeton , NJ ) has been demonstrated to be highly effective in treating patients with advanced breast cancer , including those with anthracycline-resistant breast cancer , a fact that has led to efforts to combine paclitaxel and anthracyclines . Several studies aiming to define the optimal dose and schedule of combination paclitaxel/doxorubicin have now been completed or are ongoing. Phase I/II studies have yielded encouraging preliminary response rates but quite variable toxicity profiles depending on the schedule used. These clinical trials involving combination paclitaxel/doxorubicin are reviewed, with special emphasis on the short-infusion trials."}
{"sentence": "However , anastrozole , exemestane and letrozole are associated with significantly fewer endometrial cancers , as well as venous and arterial vascular events , when compared with tamoxifen [ 9 , 10 ] .", "spans": [{"span_id": 0, "text": "anastrozole", "start": 10, "end": 21, "token_start": 2, "token_end": 2}, {"span_id": 1, "text": "exemestane", "start": 24, "end": 34, "token_start": 4, "token_end": 4}, {"span_id": 2, "text": "letrozole", "start": 39, "end": 48, "token_start": 6, "token_end": 6}, {"span_id": 3, "text": "tamoxifen", "start": 179, "end": 188, "token_start": 27, "token_end": 27}], "rels": [], "paragraph": "Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature. Aromatase inhibitors (AI's) are increasingly being incorporated in the treatment strategy for hormone receptor positive breast cancer either alone or in combination with chemotherapy, biologics in both the adjuvant and metastatic setting [1]. They markedly suppress plasma estrogen levels by inhibiting or inactivating aromatase, the enzyme responsible for the synthesis of estrogens from androgenic substrates [1]. Currently, the three selective aromatase inhibitors that are available are anastrozole, letrozole and exemestane which reduce circulating estrogen to 1 to 10% of pretreatment levels [2]. For advanced breast cancer, aromatase inhibitors appear to be at a minimum, equivalent and perhaps even better than tamoxifen in the first line setting [3, 4]. In primary breast cancer, adjuvant therapy with anastrozole or letrozole appears to be superior to tamoxifen in reducing the risk of relapse [5, 6]. Common adverse effects associated with AI's include arthralgias (21%), myalgias (12%), other musculoskeletal disorders (28%) and an up to 60% increased risk of bone fracture [7, 8]. However , anastrozole , exemestane and letrozole are associated with significantly fewer endometrial cancers , as well as venous and arterial vascular events , when compared with tamoxifen [ 9 , 10 ] . Very rarely letrozole and anastrozole can cause a skin rash; the frequency of its occurrence has not been quantified(. )However, exemestane has not been reported to cause a skin rash [11]. To date, erythema nodosum (EN) has not been reported as a dermatologic side effect of AI's. Here, we report three cases of EN which developed in postmenopausal breast cancer patients on AI's."}
{"sentence": "Additivity , synergy , or competition was observed with MIS and rapamycin , AzadC , doxorubicin , cisplatin , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone .", "spans": [{"span_id": 0, "text": "rapamycin", "start": 64, "end": 73, "token_start": 11, "token_end": 11}, {"span_id": 1, "text": "doxorubicin", "start": 84, "end": 95, "token_start": 15, "token_end": 15}, {"span_id": 2, "text": "paclitaxel", "start": 114, "end": 124, "token_start": 20, "token_end": 20}, {"span_id": 3, "text": "MIS", "start": 56, "end": 59, "token_start": 9, "token_end": 9}, {"span_id": 4, "text": "AzadC", "start": 76, "end": 81, "token_start": 13, "token_end": 13}], "rels": [{"class": "POS", "spans": [0, 3]}, {"class": "POS", "spans": [3, 4]}, {"class": "POS", "spans": [1, 3]}], "paragraph": "Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents. Mouse serous and endometrioid ovarian carcinoma cell lines were tested in vitro against rhMIS alone and with doxorubicin, paclitaxel, or cisplatin as agents in clinical use. Because MIS releases FK506 binding protein (FKBP12), which activates the mammalian target of rapamycin (mTOR) downstream of Akt, rhMIS and rapamycin combinations were tested. MIS increases p16 protein levels, and 5'-Aza-2'-deoxycytidine (AzadC) induces p16 mRNA; therefore, they were used in combination in vitro and in vivo with a human ovarian cancer cell line. A paclitaxel-resistant human ovarian cancer cell line and its parental line both respond to rhMIS in vitro. Additivity , synergy , or competition was observed with MIS and rapamycin , AzadC , doxorubicin , cisplatin , and paclitaxel , suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone . These assays and statistical analyses could be useful in selecting rhMIS and chemotherapeutic agent combinations that enhance clinical efficacy and reduce toxicity."}
{"sentence": "There was no cytotoxic effect of cisplatin , ifosfamide , and etoposide .", "spans": [{"span_id": 0, "text": "ifosfamide", "start": 45, "end": 55, "token_start": 8, "token_end": 8}, {"span_id": 1, "text": "etoposide", "start": 62, "end": 71, "token_start": 11, "token_end": 11}], "rels": [], "paragraph": "Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling. The long-term clinical outcome of pediatric intracranial epepdymoma is poor with a high rate of recurrence. One of the main reasons for this poor outcome is the tumor's inherent resistance to chemotherapy. Signal transducer and activator of transcription 3 (STAT3) is overactive in many human cancers, and inhibition of STAT3 signaling is an emerging area of interest in oncology. In this study, the possibility of STAT3 inhibition as a treatment was investigated in pediatric intracranial ependymoma tissues and cell lines. STAT3 activation status was checked in ependymoma tissues. The responses to conventional chemotherapeutic agents and a STAT3 inhibitor WP1066 in primarily cultured ependymoma cells were measured by cell viability assay. Apoptosis assays were conducted to reveal the cytotoxic mechanism of applied agents. Knockdown of STAT3 was tried to confirm the effects of STAT3 inhibition in ependymoma cells. High levels of phospho-STAT3 (p-STAT3) expression were observed in ependymoma tissue, especially in the anaplastic histology group. There was no cytotoxic effect of cisplatin , ifosfamide , and etoposide . Both brain tumor-initiating cells (BTICs) and bulk tumor cells (BCs) showed considerably decreased viability after WP1066 treatment. However, BTICs had fewer responses than BCs. No additive or synergistic effect was observed for combination therapy of WP1066 and cisplatin. WP1066 effectively abrogated p-STAT3 expression. An increased apoptosis and decreased Survivin expression were observed after WP1066 treatment. Knockdown of STAT3 also decreased cell survival, supporting the critical role of STAT3 in sustaining ependymoma cells. In this study, we observed a cytotoxic effect of STAT3 inhibitor on ependymoma BTICs and BCs. There is urgent need to develop new therapeutic agents for pediatric ependymoma. STAT3 inhibitors may be a new group of drugs for clinical application. "}
{"sentence": "Several first-line phase III trials , as well as ongoing trials for which only preliminary results have been published , have fueled debates on the optimal dose and schedule ; these have focused not only on weekly vs q3-weeks paclitaxel , but also on other modifications and the advisability of adding bevacizumab .", "spans": [{"span_id": 0, "text": "paclitaxel", "start": 226, "end": 236, "token_start": 39, "token_end": 39}, {"span_id": 1, "text": "bevacizumab", "start": 302, "end": 313, "token_start": 51, "token_end": 51}], "rels": [{"class": "COMB", "spans": [0, 1]}], "paragraph": "Carboplatin/Paclitaxel Induction in Ovarian Cancer: The Finer Points. The carboplatin/paclitaxel doublet remains the chemotherapy backbone for the initial treatment of ovarian cancer. This two-drug regimen, with carboplatin dosed using the Calvert formula, yielded convincing noninferior outcomes when compared with the prior, more toxic, regimen of cisplatin/paclitaxel. Carboplatin's dose-limiting toxicity is thrombocytopenia; however, when this drug is properly dosed and combined with paclitaxel, the doublet's cycle 1 dose in chemotherapy-naive women is generally safe. Carboplatin (unlike cisplatin) contributes minimally to the cumulative sensory neuropathy of paclitaxel, thus ensuring noticeable reversibility of neuropathy symptoms following completion of 6 cycles and only occasionally requiring cessation or substitution of the taxane. Paclitaxel is responsible for the hair loss associated with the carboplatin/paclitaxel doublet; preventive measures must be considered for patients who would otherwise refuse treatment. Several first-line phase III trials , as well as ongoing trials for which only preliminary results have been published , have fueled debates on the optimal dose and schedule ; these have focused not only on weekly vs q3-weeks paclitaxel , but also on other modifications and the advisability of adding bevacizumab . Our view is that results of this doublet in the first-line treatment of ovarian cancer are driven primarily by carboplatin, given that ovarian cancer is a platinum-sensitive disease. Consequently, the roles of the accompanying paclitaxel dose and schedule and the addition of bevacizumab are currently unsettled, and questions regarding these issues should be decided based on patient tolerance and comorbidities until additional data are available."}
{"sentence": "The primary goal was achieve the correct estimation of the target plasma area against the topotecan concentration-time curve ( AUC ) in a 5 day course of cladribine followed by monitored topotecan in pediatric patients with recurrent/refractory AML .", "spans": [{"span_id": 0, "text": "topotecan", "start": 90, "end": 99, "token_start": 15, "token_end": 15}, {"span_id": 1, "text": "cladribine", "start": 154, "end": 164, "token_start": 27, "token_end": 27}, {"span_id": 2, "text": "topotecan", "start": 187, "end": 196, "token_start": 31, "token_end": 31}], "rels": [{"class": "COMB", "spans": [1, 2]}], "paragraph": "Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis. Individualization of the topotecan dosing can reduce inter-patient variability, toxicity, and at the same time increases chemotherapy efficacy. Topotecan dosing based on simultaneous drug monitoring and pharmacokinetic analysis can yield more accurate and precise estimation of the topotecan systemic exposure than that attainable with the fixed dosing approach. Therefore, a combined approach could provide a tool assisting the clinicians in individualization of the topotecan dosing. The aim of the study was to estimate the topotecan exposure in pediatric patients with acute myeloid leukemia (AML) based on the plasma concentration-time data and using the pharmacokinetic analysis. The primary goal was achieve the correct estimation of the target plasma area against the topotecan concentration-time curve ( AUC ) in a 5 day course of cladribine followed by monitored topotecan in pediatric patients with recurrent/refractory AML . A sensitive and selective reversed-phase liquid chromatographic-mass spectrometry (LC-MS) assay was developed to quantify total topotecan in the human plasma samples. This method, with its lower quantification limit of 1 ng/ml, was validated over a linear range of 1-150 ng/ml. Under the proposed approach, the topotecan dosing was selected so as to achieve the final AUC value of 140\u00b120 ng/ml h. The presented analytical and pharmacokinetic data demonstrate that the proposed approach can be a practical, useful, efficient, and accurate tool for individualizing the topotecan dosing in children with AML."}
{"sentence": "The management of EP is challenging : no standardized guidelines exist with literature suggesting cyclosporine or infliximab as first-line therapy .", "spans": [{"span_id": 0, "text": "cyclosporine", "start": 98, "end": 110, "token_start": 14, "token_end": 14}, {"span_id": 1, "text": "infliximab", "start": 114, "end": 124, "token_start": 16, "token_end": 16}], "rels": [], "paragraph": "Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases. Erythrodermic psoriasis (EP) is a rare form of the disease clinically characterized by a generalized erythema covering \u226590% of the body surface area (BSA). The management of EP is challenging : no standardized guidelines exist with literature suggesting cyclosporine or infliximab as first-line therapy . However, a recent systematic review showed a positive response in EP patients treated with biologic agents. The most common biologic used for EP up until now has been ustekinumab, whereas infliximab might represent a first-line option in case of complicated EP (acute, severe, or unstable). Up until now, no case of brodalumab (a monoclonal antibody blocking IL-17 receptor) treatment for EP in real-life has ever been described. Here, we report the first two cases of efficacy and safety of brodalumab in real-life cases of EP."}
{"sentence": "As single agents , curcumin and metformin are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer .", "spans": [{"span_id": 0, "text": "curcumin", "start": 19, "end": 27, "token_start": 4, "token_end": 4}, {"span_id": 1, "text": "metformin", "start": 32, "end": 41, "token_start": 6, "token_end": 6}], "rels": [], "paragraph": "Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells. Effective chemoprevention is critical for improving outcomes of oral cancer. As single agents , curcumin and metformin are reported to exhibit chemopreventive properties , in vitro as well as in patients with oral cancer . In this study, the chemopreventive efficacy of this drug combination was tested in a 4-nitro quinoline-1-oxide (4NQO) induced mice oral carcinogenesis model. Molecular analysis revealed a cancer stem cell (CSC)-driven oral carcinogenic progression in this model, wherein a progressive increase in the expression of CSC-specific markers (CD44 and CD133) was observed from 8th to 25th week, at transcript (40-100-fold) and protein levels (P\u2009\u2264\u20090.0001). Chemopreventive treatment of the animals at 17th week with curcumin and metformin indicated that the combination regimen decreased tumor volume when compared to the control arm (0.69+0.03 vs 6.66+2.4\u2009mm"}
{"sentence": "Withdrawal rates were comparable to drug survival rates of other biological therapies and rates of adverse events were similar between brodalumab and ustekinumab .", "spans": [{"span_id": 0, "text": "brodalumab", "start": 135, "end": 145, "token_start": 20, "token_end": 20}, {"span_id": 1, "text": "ustekinumab", "start": 150, "end": 161, "token_start": 22, "token_end": 22}], "rels": [], "paragraph": "Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. As part of the National Institute for Health and Care Excellence single technology appraisal process, brodalumab was assessed to determine the clinical and cost effectiveness of its use in the treatment of moderate-to-severe plaque psoriasis. The Centre for Reviews and Dissemination and the Centre for Health Economics Technology Assessment Group at the University of York were commissioned to act as the independent Evidence Review Group. This article provides a summary of the Evidence Review Group's review of the company's submission, the Evidence Review Group report and the National Institute for Health and Care Excellence Appraisal Committee's subsequent guidance issued in March 2018. The main clinical effectiveness data were derived from three well-conducted, multicentre, double-blind randomised controlled trials. The trials demonstrated that brodalumab statistically significantly reduced the severity of psoriasis and its impact on health-related quality of life, compared with placebo, at 12\u00a0weeks. In comparison with ustekinumab, statistically significantly more patients taking brodalumab had reduced psoriasis severity at 12\u00a0weeks. Psoriasis severity and quality of life also appeared improved at 52\u00a0weeks, although statistical significance was not assessed. Withdrawal rates were comparable to drug survival rates of other biological therapies and rates of adverse events were similar between brodalumab and ustekinumab . A network meta-analysis was presented, comparing brodalumab with other therapies available at the same point in the treatment pathway (i.e. in patients for whom standard systemic therapy or phototherapy is inadequately effective, not tolerated or contraindicated). The network meta-analysis ranked treatments in order of effectiveness, in terms of achieving different levels of Psoriasis Area and Severity Index response. The results indicated that brodalumab had a similar probability of response to ixekizumab, secukinumab and infliximab and a higher probability of response than ustekinumab, adalimumab, etanercept, apremilast, dimethyl fumarate and placebo. The company's economic model compared nine treatment sequences that included three lines of active therapy, consisting of brodalumab and other comparators recommended by the National Institute for Health and Care Excellence, followed by best supportive care. The sequence with brodalumab in the first-line position dominated sequences that started with adalimumab, infliximab, secukinumab and ustekinumab. The incremental cost-effectiveness ratio of the brodalumab sequence compared to less effective and non-dominated sequences ranged from \u00a37145 (vs. the etanercept sequence) to \u00a313,353 (vs. the dimethyl fumarate sequence) per quality-adjusted life-year gained. The incremental cost-effectiveness ratio for the more costly and effective ixekizumab sequence was \u00a3894,010 per quality-adjusted life-year gained compared to the brodalumab sequence. At a threshold of \u00a320,000 per quality-adjusted life-year gained, the brodalumab sequence had the highest probability of being cost effective (96%). The main limitation of the company's economic model was the restrictive nature of the sequences compared. Twelve separate scenarios based on key uncertainties were explored by the Evidence Review Group. The only scenarios where brodalumab was ranked lower than first were not considered to be more appropriate or plausible than the assumptions or scenarios included in the company's base case. The treatment rankings identified in the Evidence Review Group's alternative base case were identical to those derived from the company's base case model. At the first National Institute for Health and Care Excellence Appraisal Committee meeting, the Committee concluded that brodalumab appears to be as effective as other anti-interleukin-17 agents and is cost effective, based on the discount agreed in the patient access scheme. Brodalumab is recommended as an option for treating adults with severe plaque psoriasis (defined by a total Psoriasis Area and Severity Index score of 10 or more and a Dermatology Life Quality Index score of more than 10) who have not responded to other systemic non-biological therapies. Brodalumab should be stopped at 12\u00a0weeks if the psoriasis has not responded adequately."}
{"sentence": "In patients with NPSLE , the use of high-dose corticosteroids is recommended in combination with immunosuppressants , such as mycophenolate mofetil and intravenous cyclophosphamide pulse therapy .", "spans": [{"span_id": 0, "text": "mycophenolate", "start": 126, "end": 139, "token_start": 19, "token_end": 19}, {"span_id": 1, "text": "cyclophosphamide", "start": 164, "end": 180, "token_start": 23, "token_end": 23}, {"span_id": 2, "text": "corticosteroids", "start": 46, "end": 61, "token_start": 9, "token_end": 9}, {"span_id": 3, "text": "mofetil", "start": 140, "end": 147, "token_start": 20, "token_end": 20}], "rels": [{"class": "POS", "spans": [0, 2]}, {"class": "POS", "spans": [1, 2]}, {"class": "POS", "spans": [2, 3]}], "paragraph": "[Neuropsychiatric Systemic Lupus Erythematosus]. Central nervous system damage, a major organ manifestation of systemic lupus erythematosus (SLE), causes significant morbidity and mortality. Designating this condition as neuropsychiatric SLE (NPSLE), the American College of Rheumatology defines it as involving the central and peripheral nervous systems and being characterized by various manifestations including stroke, seizures, and psychosis. NPSLE treatment mainly seeks to reduce damage accrual. In patients with NPSLE , the use of high-dose corticosteroids is recommended in combination with immunosuppressants , such as mycophenolate mofetil and intravenous cyclophosphamide pulse therapy . This can be accomplished by controlling the activity of the disease, minimizing the use of corticosteroids, and optimizing the management of comorbidities, including cardiovascular risk factors. An international task force analysis of a treat-to-target strategy for SLE (T2T/SLE) recommended targeting remission, preventing damage, and improving quality of life. Thus, more effective and less toxic treatments, such as those using biologics or kinase inhibitors, are still being developed for the treatment of SLE/NPSLE."}
{"sentence": "Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of cyclophosphamide ( CTX ) and mitoxantrone ( MXT ) , with dose escalation of paclitaxel .", "spans": [{"span_id": 0, "text": "cyclophosphamide", "start": 124, "end": 140, "token_start": 19, "token_end": 19}, {"span_id": 1, "text": "mitoxantrone", "start": 153, "end": 165, "token_start": 24, "token_end": 24}, {"span_id": 2, "text": "paclitaxel", "start": 200, "end": 210, "token_start": 33, "token_end": 33}], "rels": [{"class": "COMB", "spans": [0, 1, 2]}], "paragraph": "Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer. This study determined the effects of high-dose chemotherapy (HDCT) with autologous blood stem cell transplantation (ASCT) on quality of life (QL) in women with metastatic breast cancer prior to, and during treatment, and up to 1-year post-ASCT. Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of cyclophosphamide ( CTX ) and mitoxantrone ( MXT ) , with dose escalation of paclitaxel . Longitudinal QL data were collected using the functional living index-cancer (FLIC) and symptom scales at seven time periods: pre-induction chemotherapy (CT), post-induction CT, post-high dose CT (HDCT), and at 3, 6, 9 and 12 months post-ASCT. FLIC scores indicated that the worst problems for patients were feelings of hardship on themselves and their families, followed by psychological functioning and physical functioning problems. The time around diagnosis of the metastatic disease and following HDCT were the worst times for all levels of quality of life, but anxiety and depression symptoms continued to increase in severity across the entire follow-up period. The symptoms that were most problematic were worry about the future, loss of sexual interest, anxiety about the treatment, general worrying, and joint pain. These data highlight the problems that women with metastatic breast cancer encounter at different stages of the disease and treatment process, and can be used to tailor psychosocial interventions appropriate for treating the relevant issues at different points in time."}
{"sentence": "These studies suggest a slight advantage to the combined approaches that contain flutamide and bicalutamide , but the lack of dramatic differences in outcome makes monotherapy reasonable , especially in patients with more indolent disease .", "spans": [{"span_id": 0, "text": "flutamide", "start": 81, "end": 90, "token_start": 12, "token_end": 12}, {"span_id": 1, "text": "bicalutamide", "start": 95, "end": 107, "token_start": 14, "token_end": 14}], "rels": [{"class": "POS", "spans": [0, 1]}], "paragraph": "The selection of hormonal therapy in prostate cancer: who, when, and for how long? Androgen deprivation is the foundation for the systemic therapy of advanced prostate cancer. Multiple trials have tested combined androgen blockade versus androgen deprivation alone in patients with advanced disease. These studies suggest a slight advantage to the combined approaches that contain flutamide and bicalutamide , but the lack of dramatic differences in outcome makes monotherapy reasonable , especially in patients with more indolent disease . Intermittent androgen deprivation is an alternative that may allow patients to reduce the total time on androgen suppression as well as possibly delay the onset of androgen independence. A number of secondary hormonal therapies, including deferred and secondary antiandrogens, ketoconazole, and estrogens have shown modest response proportions. Patients with less advanced disease such as a rising prostate-specific antigen have varied outcomes, and no standard approach exists. In this group, noncastrating forms of hormonal therapy are being evaluated. Patients undergoing definitive local therapy who have high-risk features may benefit from early, as opposed to deferred, androgen deprivation. This review examines the evidence for the current state of the art in hormonal therapy in patients with prostate cancer and focuses, in particular, on treatment composition and timing as well as the rationale for the use of hormonal therapy in early stage disease."}
{"sentence": "We examined the feasibility and safety of using paclitaxel and trastuzumab as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer .", "spans": [{"span_id": 0, "text": "paclitaxel", "start": 48, "end": 58, "token_start": 8, "token_end": 8}, {"span_id": 1, "text": "trastuzumab", "start": 63, "end": 74, "token_start": 10, "token_end": 10}], "rels": [{"class": "POS", "spans": [0, 1]}], "paragraph": "Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.  We examined the feasibility and safety of using paclitaxel and trastuzumab as maintenance therapy after high-dose chemotherapy ( HDC ) with autologous hematopoietic stem cell transplantation ( AHST ) for patients with HER2-positive metastatic breast cancer . Ten patients (9 women and 1 man) were enrolled in the study. The median age was 46.5 years (range, 27-65 years). The median follow-up time was 1003 days (range, 216-2526 days). All patients had metastatic disease, but 2 had only bone metastasis. One patient had complete response, 6 had partial response and 3 had stable disease to the standard-dose chemotherapy prior to transplantation. The conditioning regimen consisted of cyclophosphamide, carmustine, and thiotepa. After AHST, patients received weekly paclitaxel for 12 doses and trastuzumab every 3 weeks for 1 year as maintenance therapy. All patients experienced successful engraftment. The only grade 4 toxic effects observed were leukopenia and thrombocytopenia. The most common grade 3 toxic effect was neutropenic fever. No treatment-related deaths were observed. The median progression-free survival time was 441 days, and the median overall survival time was 955 days. Two patients died in accidents while their disease remained in remission. Five patients died with disease progression. At the time of this report, 3 patients are alive with stable disease, 1 of whom has remained free of disease progression for 2526 days since transplantation. Our findings indicate that paclitaxel plus trastuzumab as maintenance therapy after HDC with AHST for patients with HER2-positive metastatic breast cancer not only is feasible and safe but also results in survival outcomes similar to historical results. "}
{"sentence": "Dual antiplatelet therapy with aspirin and clopidogrel ( the preferred thienopyridine because of its superior hematologic safety ) is recommended for at least 4 weeks to prevent subacute stent thrombosis with bare-metal stents and 3 to 6 months to prevent late-stent thrombosis with drug-eluting stents .", "spans": [{"span_id": 0, "text": "aspirin", "start": 31, "end": 38, "token_start": 4, "token_end": 4}, {"span_id": 1, "text": "clopidogrel", "start": 43, "end": 54, "token_start": 6, "token_end": 6}], "rels": [{"class": "POS", "spans": [0, 1]}], "paragraph": "Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy. Arterial wall injury caused by percutaneous coronary intervention (PCI) triggers transient platelet activation and mural thrombosis; these effects are superimposed on the preexisting platelet hyperreactivity associated with underlying atherothrombosis. Platelet activation has been implicated in the major complications of PCI: acute and subacute thrombosis and restenosis. Antithrombotic and anticoagulant therapy minimizes thrombotic complications after PCI. Aspirin plus a thienopyridine (ticlopidine or clopidogrel) is more effective than aspirin plus heparin and extended warfarin therapy in preventing periprocedural ischemic events and subsequent stent thrombosis and results in less major and minor bleeding. Dual antiplatelet therapy with aspirin and clopidogrel ( the preferred thienopyridine because of its superior hematologic safety ) is recommended for at least 4 weeks to prevent subacute stent thrombosis with bare-metal stents and 3 to 6 months to prevent late-stent thrombosis with drug-eluting stents . Coronary atherothrombosis is a diffuse vascular disease, and reduction of the risk of future ischemic events requires strategies that extend beyond the focal treatment of stenotic lesions. Optimal long-term care after PCI requires aggressive systemic pharmacotherapy (antiplatelet agents, statins, beta-blockers, and angiotensin-converting enzyme Inhibitors) in conjunction with therapeutic lifestyle changes (smoking cessation, weight reduction, dietary measures, and exercise). In this context, dual antiplatelet therapy (aspirin plus clopidogrel) is recommended for at least 12 months after PCI for prophylaxis of future atherothrombotic events."}
{"sentence": "Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens , apalutamide and enzalutamide , when used in combination with ADT , have demonstrated a significant benefit in metastasis-free survival .", "spans": [{"span_id": 0, "text": "apalutamide", "start": 122, "end": 133, "token_start": 16, "token_end": 16}, {"span_id": 1, "text": "enzalutamide", "start": 138, "end": 150, "token_start": 18, "token_end": 18}, {"span_id": 2, "text": "ADT", "start": 183, "end": 186, "token_start": 25, "token_end": 25}], "rels": [{"class": "POS", "spans": [0, 2]}, {"class": "POS", "spans": [1, 2]}], "paragraph": "Recent trends in the management of advanced prostate cancer. Advanced prostate cancer includes a wide spectrum of disease ranging from hormone na\u00efve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or abiraterone acetate to ADT results in significant survival advantage as compared with ADT alone. Furthermore , in non-metastatic castration-resistant prostate cancer ( M0 CRPC ) , two second-generation anti-androgens , apalutamide and enzalutamide , when used in combination with ADT , have demonstrated a significant benefit in metastasis-free survival . Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer."}
{"sentence": "A screening method based on liquid chromatography-electrospray mass spectrometry for the simultaneous determination of six corticosteroids ( betamethasone 17-valerate BM 17-V , beclomethasone BC , beclomethasone dipropionate BCDP , methylprednisolone MP , budesonide BD , flunisolide FN ) was developed in order to control their illegal use in cosmetic and natural products .", "spans": [{"span_id": 0, "text": "betamethasone", "start": 141, "end": 154, "token_start": 17, "token_end": 17}, {"span_id": 1, "text": "beclomethasone", "start": 177, "end": 191, "token_start": 22, "token_end": 22}, {"span_id": 2, "text": "beclomethasone", "start": 197, "end": 211, "token_start": 25, "token_end": 25}, {"span_id": 3, "text": "methylprednisolone", "start": 232, "end": 250, "token_start": 29, "token_end": 29}, {"span_id": 4, "text": "budesonide", "start": 256, "end": 266, "token_start": 32, "token_end": 32}], "rels": [], "paragraph": "LC-MS method for the simultaneous determination of six glucocorticoids in pharmaceutical formulations and counterfeit cosmetic products.  A screening method based on liquid chromatography-electrospray mass spectrometry for the simultaneous determination of six corticosteroids ( betamethasone 17-valerate BM 17-V , beclomethasone BC , beclomethasone dipropionate BCDP , methylprednisolone MP , budesonide BD , flunisolide FN ) was developed in order to control their illegal use in cosmetic and natural products . Indeed, despite corticosteroids are banned in cosmetics, counterfeit products might be present on the market, representing a health hazard. Therefore, effective analytical methods are required to rapidly screen over the counter products in health care shops for counterfeit corticosteroids. The analytical method involves the employment of a Waters Synergy C18 column (150mm\u00d72.0mm I.D.) by using the following mobile phase: A (0.1% formic acid in acetonitrile), B (0.1% formic acid in water) in a linear gradient (from A-B 25:75, v/v to A-B 95:5, v/v in 30min) at the flow rate of 0.3mL/min. The detection was performed with an ion trap (IT) mass spectrometer in positive polarity, total ion current (TIC) and tandem mass modalities for qualitative purpose; single ion monitoring (SIM) mode was used for quantitative analysis on the ESI generated most abundant ion for each steroid. The method was fully validated in terms of precision, detection and quantification limits, linearity, recovery, and it was applied to the identification and quantification of corticosteroids in pharmaceutical formulations and cosmetic products. The mean recovery of BM 17-V, BC, BCDP, MP, BD and FN were found to be 101.3, 101.5, 98.8, 98.9, 98.1, 99.0%, respectively. Limits of quantitation (LOQ) were comprised in the range 29-95ng/mL. To the best of our knowledge, for the first time this mix of glucocorticoids were simultaneously determined in cosmetic products by using a fully validated method. BMV, in its two isomeric forms BM 17-V and BM 21-V, was found to be illegally present in one cream sample (A) with the total concentration level of 0.036% (w/w). "}
{"sentence": "Caspofungin and amphotericin B association has been shown to be synergistic in vitro and effective in murine models .", "spans": [{"span_id": 0, "text": "Caspofungin", "start": 0, "end": 11, "token_start": 0, "token_end": 0}, {"span_id": 1, "text": "amphotericin", "start": 16, "end": 28, "token_start": 2, "token_end": 2}], "rels": [{"class": "POS", "spans": [0, 1]}], "paragraph": "[Successful treatment of a persistent rhino-cerebral mucormycosis in a pediatric patient with a debut of acute lymphoblastic leukemia]. The fungi of the order Mucorales cause mucormycosis, which usually presents as an invasive fungal disease with rapid angioinvasion in immunocompromised patients. Rhinocerebral is the most common presentation. The lipid formulations of amphotericin B are used as primary treatment in invasive mucormycosis; the combined use of posaconazole could allow a reduction in the dose of amphotericin B improving tolerance and adherence to treatment. Caspofungin and amphotericin B association has been shown to be synergistic in vitro and effective in murine models . We present the case of a preschool patient that during the debut of acute lymphoblastic leukemia developed a rhinocerebral mucormycosis successfully responding to antifungal treatment with the combination of liposomal amphotericin and caspofungin. "}
{"sentence": "Canine leishmaniosis is most frequently treated with the drugs meglumine antimoniate , allopurinol , amphotericin B , or a combination of meglumine antimoniate and allopurinol .", "spans": [{"span_id": 0, "text": "meglumine", "start": 63, "end": 72, "token_start": 9, "token_end": 9}, {"span_id": 1, "text": "allopurinol", "start": 87, "end": 98, "token_start": 12, "token_end": 12}, {"span_id": 2, "text": "amphotericin", "start": 101, "end": 113, "token_start": 14, "token_end": 14}, {"span_id": 3, "text": "meglumine", "start": 138, "end": 147, "token_start": 21, "token_end": 21}, {"span_id": 4, "text": "allopurinol", "start": 164, "end": 175, "token_start": 24, "token_end": 24}, {"span_id": 5, "text": "antimoniate", "start": 73, "end": 84, "token_start": 10, "token_end": 10}], "rels": [{"class": "POS", "spans": [3, 4]}, {"class": "POS", "spans": [1, 2, 5]}], "paragraph": "Chemotherapy of canine leishmaniosis. Visceral leishmaniosis is a widespread and potentially fatal disease of dogs and humans common in the Mediterranean region, the Middle East, and South America. Canine leishmaniosis is most frequently treated with the drugs meglumine antimoniate , allopurinol , amphotericin B , or a combination of meglumine antimoniate and allopurinol . Therapy with the currently used drugs often achieves temporary clinical improvement and changes in immunologic parameters with restoration of the ability to mount parasite-specific cell mediated responses and decrease in anti-leishmanial antibody titers. However, treatment usually does not prevent relapse of disease or eliminate parasite carriage. Due to the current lack of an ultimate and effective therapy for canine leishmaniosis, new drugs, delivery systems and treatment strategies are necessary to achieve a consistent parasitological cure in infected dogs."}
{"sentence": "Haloperidol , carbamazepine and levomepromazine were then discontinued .", "spans": [{"span_id": 0, "text": "Haloperidol", "start": 0, "end": 11, "token_start": 0, "token_end": 0}, {"span_id": 1, "text": "carbamazepine", "start": 14, "end": 27, "token_start": 2, "token_end": 2}], "rels": [{"class": "COMB", "spans": [0, 1]}], "paragraph": "Pituitary microadenoma treated with antipsychotic drug aripiprazole. Male patient 24 years old with a pituitary microadenoma and mental and behavioural disorders due to multiple drug use and use of other psychoactive substances (cocaine, cannabis and alcohol) were treated with haloperidol (dopamine receptor blocker) 10 mg daily. In the last control, the patient presented mammary hypertrophy; laboratory testing and brain magnetic resonance imaging (MRI) was performed, reporting the presence of a pituitary microadenoma syndrome with hormonal alteration (Prolactin levels 28.4 ng/ml). Haloperidol , carbamazepine and levomepromazine were then discontinued . He was started on aripiprazole 15 mg po daily for 4 days; the dosage was then increased to 30 mg po daily, with valproic Acid 500 mg po tid. After 3 weeks on aripiprazole, the mammary hypertrophy that had increased in the patient had resolved. After 10 weeks follow up of prolactin revealed a normal level, at 4.33 ng/ml. Insomnia, aggressiveness, irritability, visual, tactile and auditory hallucinations remained absent after treatment with aripiprazole which is not a first line drug in multiple drug use patient with psychosis. We also consider the correlation of drug use in patient with psychosis, haloperidol treatment, pituitary microadenoma syndrome, hyperprolactinemia, and dopamine D2- receptor partial agonist aripiprazole treatment. This article also summarizes some relevant patents."}
{"sentence": "Recent clinical work has questioned the safety of a combined therapy of oral quinidine and intravenous verapamil , because some patients were reported to react with severe hypotension probably due to drug interactions with vascular alpha-adrenergic receptors .", "spans": [{"span_id": 0, "text": "quinidine", "start": 77, "end": 86, "token_start": 13, "token_end": 13}, {"span_id": 1, "text": "verapamil", "start": 103, "end": 112, "token_start": 16, "token_end": 16}], "rels": [{"class": "NEG", "spans": [0, 1]}], "paragraph": "Additive competitive interaction of verapamil and quinidine at alpha-adrenergic receptors of isolated cardiac guinea pig myocytes and human platelets.  Recent clinical work has questioned the safety of a combined therapy of oral quinidine and intravenous verapamil , because some patients were reported to react with severe hypotension probably due to drug interactions with vascular alpha-adrenergic receptors . In order to obtain further quantitative information on the underlying mechanism, we used the radioligands (3H)-prazosin and (3H)-yohimbine to perform binding studies on intact cells, with predominantly alpha-1 (isolated myocytes) or alpha-2 subtypes (human platelets) of adrenergic receptors. Our studies confirm that both verapamil and quinidine possess a distinct alpha-adrenergic receptor blocking activity and do not discriminate between the alpha-1 and alpha-2 subtype (Ki-values were between 0.24-0.28 mumol/l for alpha-1 receptors and 0.49-0.50 mumol/l for alpha-2 receptors). Their interaction was competitive and in the presence of both drugs inhibition of radioligand binding was additive. The alpha-adrenergic blockade by verapamil was stereospecific as D-verapamil increased the dissociation constant of the radioligand to a much lesser degree than L-verapamil (Ki = 1.67 +/- 0.29 mumol/l for D-verapamil). The calcium channel blocker nitrendipine, a 1,4-dihydropyridine derivative, did not show any competition up to concentrations of 10 mumol/l. Our results thus give evidence that verapamil and quinidine have already at therapeutic blood levels significant alpha-adrenergic blocking activities which may be of clinical interest. In addition our results show that adult cardiac myocytes are very well suited for pharmacological adrenergic interaction studies."}
{"sentence": "The mean duration of total ( i.v . and oral ) therapy was significantly shorter for the azithromycin group than for the cefuroxime group ( 6.2 days vs 10.1 days ) .", "spans": [{"span_id": 0, "text": "azithromycin", "start": 88, "end": 100, "token_start": 17, "token_end": 17}, {"span_id": 1, "text": "cefuroxime", "start": 120, "end": 130, "token_start": 22, "token_end": 22}], "rels": [], "paragraph": "Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study. An international, randomized, open-label, comparative study was undertaken in order to assess the efficacy and safety of azithromycin and cefuroxime, short sequential vs standard sequential therapy, respectively, in the treatment of patients with community-acquired pneumonia (CAP). 180 adult patients were included in the study. 89 patients received azithromycin 500 mg intravenously (i.v.) once daily for 1-4 days followed by azithromycin 500 mg orally once daily for 3 days. 91 patients received cefuroxime 1.5 g i.v. three times daily for 1-4 days followed by cefuroxime axetil 500 mg orally twice daily for 7 days. Clinical efficacy was achieved in 67/82 (81.7%) patients treated with azithromycin, and in 73/89 (82.0%) patients treated with cefuroxime. The mean duration of total ( i.v . and oral ) therapy was significantly shorter for the azithromycin group than for the cefuroxime group ( 6.2 days vs 10.1 days ) . Adverse events were recorded in 38.2% of patients treated with azithromycin, and in 29.7% of patients treated with cefuroxime (p = 0.20). Shorter sequential i.v.-to-oral azithromycin therapy of patients with CAP was as effective as standard sequential i.v.-to-oral cefuroxime therapy."}
{"sentence": "To increase the dose-intensity of two drugs in metastatic breast cancer , we tested the feasibility , in phase I studies , of two schedules of epirubicin ( E ) and cyclophosphamide ( C ) - sequential ( E-- > C ) and alternating ( E/C ) - with respect to the standard combination ( EC ) .", "spans": [{"span_id": 0, "text": "epirubicin", "start": 143, "end": 153, "token_start": 26, "token_end": 26}, {"span_id": 1, "text": "cyclophosphamide", "start": 164, "end": 180, "token_start": 31, "token_end": 31}], "rels": [{"class": "POS", "spans": [0, 1]}], "paragraph": "The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.  To increase the dose-intensity of two drugs in metastatic breast cancer , we tested the feasibility , in phase I studies , of two schedules of epirubicin ( E ) and cyclophosphamide ( C ) - sequential ( E-- > C ) and alternating ( E/C ) - with respect to the standard combination ( EC ) . Drugs were given at three planned-dose levels, plus either G-CSF or GM-CSF. Patients with metastatic (30), inoperable stage IIIb (2) or inflammatory (7) breast cancer were treated. The doses of EC, given every 21 days (4 cycles), were 75/1500, 82.5/2250, 90/3000 mg/m2. In the E/C schedule, epirubicin was given at cycles 1, 3 and 5, and cyclophosphamide at cycles 2, 4 and 6. In the E--> C schedule, three cycles of epirubicin then three cycles of cyclophosphamide were administered. In both experimental schedules, drugs were given every 14 days for 6 cycles at doses of 100, 110, 120 mg/m2 (E) and 2000, 3000, 4000 mg/m2 (C). The average relative dose-intensity was 1.2-fold and 2-fold greater with E/C and E--> C, respectively, than with EC. The third level dose was feasible with all schedules. Grade 4 leucopenia occurred in 77% of patients. Thrombocytopenia was absent in 6 cases and grade 4 in 12 (30.8%). Eighty-one percent of patients on experimental schedules required red blood cell support versus 44.4% of patients on EC. At the third level, platelet transfusions were more frequent among patients treated with EC (27. 8%). Non-haematological toxicity was mild: about 20% of patients experienced grade 3 vomiting, irrespective of schedule. Only 2 patients had grade 3 mucositis; no patient developed heart failure. Fever (61% of patients) and bone pain (55.5% of patients) were relevant in the GM-CSF treated groups and 12 patients shifted to G-CSF. The overall response rate was 84.6%: 5/39 (12.8%) complete response and 28/39 (71.8%) partial response. At 30/9/98, median survival was 29.5 months, with no difference between patients with metastatic and stage IIIb/inflammatory breast cancer. Median follow-up of surviving patients was 62 months (range 17-83). The 5-year estimated survival was 19% (95% confidence intervals = 7-31%). Rapidly alternating or sequential cycles of epirubicin and cyclophosphamide with CSF support is a feasible strategy that allows a higher increase of dose-intensity of the single drugs. Hospitalization and anemia were more frequent with the experimental schedules, and thrombocytopenia with the standard schedule. Overall, this intensified therapy was very active."}
{"sentence": "On February 3 , 2015 , the FDA granted accelerated approval to palbociclib ( IBRANCE , Pfizer Inc. ) , an inhibitor of cyclin-dependent kinases 4 and 6 ( CDK4 and CDK6 ) , for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive , HER2-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease .", "spans": [{"span_id": 0, "text": "palbociclib", "start": 63, "end": 74, "token_start": 12, "token_end": 12}, {"span_id": 1, "text": "letrozole", "start": 200, "end": 209, "token_start": 39, "token_end": 39}], "rels": [{"class": "POS", "spans": [0, 1]}], "paragraph": "FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.  On February 3 , 2015 , the FDA granted accelerated approval to palbociclib ( IBRANCE , Pfizer Inc. ) , an inhibitor of cyclin-dependent kinases 4 and 6 ( CDK4 and CDK6 ) , for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive , HER2-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease . The approval is based on a randomized, multicenter, open-label phase I/II trial (PALOMA-1) in 165 patients randomized to palbociclib (125 mg orally daily for 21 consecutive days, followed by 7 days off treatment) plus letrozole (2.5 mg orally daily) or letrozole alone. The phase II portion of the trial was divided into two cohorts: cohort 1 enrolled 66 biomarker-unselected patients and cohort 2 enrolled 99 biomarker-positive patients. The major efficacy outcome measure was investigator-assessed progression-free survival (PFS). A large magnitude of improvement in PFS was observed in patients receiving palbociclib plus letrozole compared with patients receiving letrozole alone (HR, 0.488; 95% confidence interval, 0.319-0.748). Multiple sensitivity analyses were supportive of clinical benefit. The most common adverse reaction in patients receiving palbociclib plus letrozole was neutropenia. This article summarizes the FDA thought process and data supporting accelerated approval based on PALOMA-1 that may be contingent upon verification and description of clinical benefit in the ongoing and fully accrued confirmatory trial PALOMA-2."}
{"sentence": "a combination treatment : estramustine phosphate , cyproterone acetate or estrogens plus bromocriptine .", "spans": [{"span_id": 0, "text": "estramustine", "start": 26, "end": 38, "token_start": 4, "token_end": 4}, {"span_id": 1, "text": "cyproterone", "start": 51, "end": 62, "token_start": 7, "token_end": 7}, {"span_id": 2, "text": "bromocriptine", "start": 89, "end": 102, "token_start": 12, "token_end": 12}, {"span_id": 3, "text": "estrogens", "start": 74, "end": 83, "token_start": 10, "token_end": 10}], "rels": [{"class": "POS", "spans": [0, 1]}, {"class": "POS", "spans": [2, 3]}], "paragraph": "[Current aspects of hormonal therapy in prostate cancer]. The following endocrine treatment modalities have been used in advanced prostatic carcinoma: 1. orchiectomy plus estrogens; 2. primary orchiectomy with delayed estrogen employment; 3. initial estrogen therapy with delayed orchiectomy; 4. initial cyproterone acetate or medroxyprogesterone acetate; 5. a combination treatment : estramustine phosphate , cyproterone acetate or estrogens plus bromocriptine . The application of phase-III studies permits the subsequent conclusions: Simultaneous orchiectomy is to no advantage (exception: urinary stasis). cyproterone acetate does neither yield better nor worse results regarding survival than estrogen alone, but has fewer side effects. Estrogens and cyproterone acetate produce a rise of serum prolactin justifying the use of bromocriptine (or lisuride). estramustine phosphate should be reserved for relapsing prostatic cancer."}
{"sentence": "Hormone induced elevations in temperature and possibly other unidentified factors during thyroid crisis may facilitate the triggering of MH following halothane and succinylcholine challenge .", "spans": [{"span_id": 0, "text": "halothane", "start": 150, "end": 159, "token_start": 20, "token_end": 20}, {"span_id": 1, "text": "succinylcholine", "start": 164, "end": 179, "token_start": 22, "token_end": 22}], "rels": [{"class": "COMB", "spans": [0, 1]}], "paragraph": "Differential diagnosis of thyroid crisis and malignant hyperthermia in an anesthetized porcine model. The intra-operative differential diagnosis between thyroid crisis and malignant hyperthermia can be difficult. Also stress alone can trigger MH. The purposes of this study were: 1) to investigate the metabolic and hemodynamic differences between thyroid crisis and MH, 2) determine how thyroid crisis affects the development of MH, and 3) determine if the stress of thyroid crisis can trigger MH in susceptible individuals. We studied MH susceptible and normal swine. Two groups of animals (MH susceptible and normal) were induced into thyroid crisis (critical core hyperthermia, sustained tachycardia and increase in oxygen consumption) by pretreatment with intraperitoneal triiodothyronine (T3) followed by large hourly intravenous injections of T3. Two similar groups were given intravenous T3 but no pretreatment. These animals did not develop thyroid crisis and served as controls. Thyroid crisis did not result in metabolic changes or rigidity characteristic of an acute episode of MH. When the animals were subsequently challenged with MH triggering agents (halothane plus succinylcholine) dramatic manifestations of fulminant MH episodes (acute serious elevation in exhaled carbon dioxide, arterial CO2, rigidity and acidemia) were noted only in the MH susceptible animals. Although thyroid crisis did not trigger MH in the susceptible animals it did decrease the time to trigger MH (14.1 +/- 7.2 minutes versus 47.2 +/- 17.7 minutes, p < 0.01) in susceptible animals. Hormone induced elevations in temperature and possibly other unidentified factors during thyroid crisis may facilitate the triggering of MH following halothane and succinylcholine challenge ."}
{"sentence": "Mitomycin C plus vinblastine is an effective and well-tolerated regimen for anthracycline resistant cancer .", "spans": [{"span_id": 0, "text": "Mitomycin", "start": 0, "end": 9, "token_start": 0, "token_end": 0}, {"span_id": 1, "text": "vinblastine", "start": 17, "end": 28, "token_start": 3, "token_end": 3}], "rels": [{"class": "POS", "spans": [0, 1]}], "paragraph": "Mitomycin C and vinblastine in anthracycline-resistant metastatic breast cancer: a phase II study. The purpose of this phase II study was to evaluate the clinical efficacy of mitomycin C and vinblastine in patients with anthracycline-resistant metastatic breast cancer. This single-center, non-randomized trial enrolled 39 patients. Eligible patients must have received at least three chemotherapy regimens with epirubicin or CAF and had treatment failure while on chemotherapy or within 6 months of completing therapy. Treatment consisted of mitomycin C at a starting dose of 8 mg/m2 on day 1 and vinblastine (8 mg/m2, days 1 and 28). The regimen was repeated every 6 weeks with a 20% dose escalation of both drugs after the first cycle in the absence of grade III hematologic or other toxicity. On an intent-to-treat basis, 38 patients were eligible for assessment; 9 (23.7%, 95% confidence interval 1.92-2.45%) achieved a partial response and 13 (34.2%) had stable disease. The median time to disease progression was 6.21+/-4.26 months (range, 1-15; 95% confidence interval, 4.81-7.61), and the median survival was 10.76+/-7.6 (range, 1-29; 95% confidence interval 8.0-13.1%). Responsive patients had a significantly better survival than those with stable and progressive disease. Treatment was well tolerated. Anemia and neutropenia (grade I-III) developed in 28.9% and 26.3% of the patients, respectively. One patient with grade III granulocytopenia developed fever and infection that required hospitalization. Moderate neurotoxicity, myalgia, constipation, diarrhea and alopecia were observed. No toxic death occurred. Mitomycin C plus vinblastine is an effective and well-tolerated regimen for anthracycline resistant cancer ."}
{"sentence": "An angiotensin 2 type 1 receptor blocker , olmesartan , and a calcium channel blocker , azelnidipine , possess not only an antihypertensive effect but also an antioxidative effect and other beneficial effects .", "spans": [{"span_id": 0, "text": "olmesartan", "start": 43, "end": 53, "token_start": 8, "token_end": 8}, {"span_id": 1, "text": "azelnidipine", "start": 88, "end": 100, "token_start": 16, "token_end": 16}], "rels": [{"class": "POS", "spans": [0, 1]}], "paragraph": "Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke-prone spontaneously hypertensive rats.  An angiotensin 2 type 1 receptor blocker , olmesartan , and a calcium channel blocker , azelnidipine , possess not only an antihypertensive effect but also an antioxidative effect and other beneficial effects . In the present study, we examined the efficacy of olmesartan and azelnidipine monotherapy (2 mg/kg or 10 mg/kg each) and their combination therapy (1 mg/kg each) on stroke-prone spontaneously hypertensive rats (SHR-SP) in relation to oxidative stress, inflammation, and the neurovascular unit. In comparison with the vehicle group, body weight, regional cerebral blood flow, and motor function were preserved, whereas systolic blood pressure and diastolic blood pressure decreased in the five drug-treatment groups. Spontaneous infarct volume decreased with the low-dose combination of olmesartan plus azelnidipine and with the high-dose olmesartan, with a further decrease in the high-dose azelnidipine group. In addition, these drugs dose-dependently reduced oxidative stresses, proinflammatory molecules, and well-preserved components of the neurovascular unit. The low-dose combination of olmesartan plus azelnidipine showed a better effect than the low-dose olmesartan or azelnidipine monotherapy. The present study shows that the low-dose combination of olmesartan plus azelnidipine demonstrates a greater synergistic benefit than monotherapy with a low-dose of olmesartan or azelnidipine in SHR-SP for preventing spontaneous infarct volume, reducing oxidative stresses and proinflammatory molecules, and imparting neurovascular protection. In addition, a high-dose of olmesartan showed a greater benefit without the lowering of blood pressure, probably because of the antioxidative and anti-inflammatory effects. A high dose of azelnidipine showed the best benefit, probably because of the two effects mentioned above related to the lowering of blood pressure."}
{"sentence": "Forty patients with metastatic breast cancer who had received no previous cytotoxic therapy were treated with a combination chemotherapy program CMF ( P ) , which included methotrexate , 60 mg/m2 , and 5-fluorouracil , 700 mg/m2 intravenously on the first and eighth days , in addition to cyclophosphamide , 100 mg/m2 , and prednisone , 40 mg/m2 , by mouth daily from the first to the fourteenth day of a 28-day cycle .", "spans": [{"span_id": 0, "text": "methotrexate", "start": 172, "end": 184, "token_start": 27, "token_end": 27}, {"span_id": 1, "text": "cyclophosphamide", "start": 289, "end": 305, "token_start": 48, "token_end": 48}, {"span_id": 2, "text": "prednisone", "start": 324, "end": 334, "token_start": 54, "token_end": 54}, {"span_id": 3, "text": "5-fluorouracil", "start": 202, "end": 216, "token_start": 33, "token_end": 33}], "rels": [{"class": "POS", "spans": [0, 1, 2, 3]}], "paragraph": "Combination chemotherapy for advanced breast cancer: response and effect on survival.  Forty patients with metastatic breast cancer who had received no previous cytotoxic therapy were treated with a combination chemotherapy program CMF ( P ) , which included methotrexate , 60 mg/m2 , and 5-fluorouracil , 700 mg/m2 intravenously on the first and eighth days , in addition to cyclophosphamide , 100 mg/m2 , and prednisone , 40 mg/m2 , by mouth daily from the first to the fourteenth day of a 28-day cycle . Only 2 of 25 patients responded to hormonal therapy or endocrine ablation. Twenty-seven of the 40 patients (68%) had a complete response (8 patients) or partial response (19 patients). Lung, soft tissue, and nodal metastases were the most responsive sites. The median survival of 18 months for the responding group. The nonresponders had a median survival of 4 months. The toxicity was primarily hematologic and was especially severe in patients with functional liver impairment due to metastatic disease."}
{"sentence": "Isoniazid , a first-line antibiotic used for the treatment of tuberculosis , is a prodrug that requires activation by the Mycobacterium tuberculosis enzyme KatG. The KatG(S315 T ) mutation causes isoniazid resistance while the KatG(R463L ) variation is thought to be a polymorphism .", "spans": [{"span_id": 0, "text": "Isoniazid", "start": 0, "end": 9, "token_start": 0, "token_end": 0}, {"span_id": 1, "text": "isoniazid", "start": 196, "end": 205, "token_start": 30, "token_end": 30}], "rels": [], "paragraph": "Purification and characterization of Mycobacterium tuberculosis KatG, KatG(S315T), and Mycobacterium bovis KatG(R463L).  Isoniazid , a first-line antibiotic used for the treatment of tuberculosis , is a prodrug that requires activation by the Mycobacterium tuberculosis enzyme KatG. The KatG(S315 T ) mutation causes isoniazid resistance while the KatG(R463L ) variation is thought to be a polymorphism . Much of the work to date focused on isoniazid activation by KatG has utilized recombinant enzyme overexpressed in Escherichia coli. In this work, native KatG and KatG(S315T) were purified from M. tuberculosis, and KatG(R463L) was purified from Mycobacterium bovis. The native molecular weight, enzymatic activity, optical, resonance Raman, and EPR spectra, K(D) for isoniazid binding, and isoniazid oxidation rates were measured and compared for each native enzyme. Further, the properties of the native enzymes were compared and contrasted with those reported for recombinant KatG, KatG(S315T), and KatG(R463L) in order to assess the ability of the recombinant enzymes to act as good models for the native enzymes."}
{"sentence": "At present , it seems to us that progress has not been made since Grignani reported a phase II cohort trial of sorafenib and sorafenib combined with everolimus for advanced osteosarcoma , which , in a sense , have become a milestone as a second-line therapy for osteosarcoma .", "spans": [{"span_id": 0, "text": "sorafenib", "start": 111, "end": 120, "token_start": 22, "token_end": 22}, {"span_id": 1, "text": "sorafenib", "start": 125, "end": 134, "token_start": 24, "token_end": 24}, {"span_id": 2, "text": "everolimus", "start": 149, "end": 159, "token_start": 27, "token_end": 27}], "rels": [{"class": "COMB", "spans": [1, 2]}], "paragraph": "Anti-angiogenesis target therapy for advanced osteosarcoma (Review). Osteosarcomas (OS), especially those with metastatic or unresectable disease, have limited treatment options. The greatest advancement in treatments occurred in the 1980s when multi-agent chemotherapy, including doxorubicin, cisplatin, high-dose methotrexate, and, in some regimens, ifosfamide, was demonstrated to improve overall survival compared with surgery alone. However, standard chemotherapeutic options have been limited by poor response rates in patients with relapsed or advanced cases. It has been reported that VEGFR expression correlates with the outcome of patients with osteosarcoma and circulating VEGF level has been associated with the development of lung metastasis. At present , it seems to us that progress has not been made since Grignani reported a phase II cohort trial of sorafenib and sorafenib combined with everolimus for advanced osteosarcoma , which , in a sense , have become a milestone as a second-line therapy for osteosarcoma . Although the recognization of muramyltripepetide phosphatidyl-ethanolamine has made some progress based on its combination with standard chemotherapy, its effect on refractory cases is controversial. Personalized comprehensive molecular profiling of high-risk osteosarcoma up to now has not changed the therapeutic prospect of advanced osteosarcoma significantly. Thus, how far have we moved forward and what therapeutic strategy should we prefer for anti-angiogenesis therapy? This review provides an overview of the most updated anti-angiogenesis therapy in OS and discusses some clinical options in order to maintain or even improve progression-free survival."}
{"sentence": "Failure to sedate patients who might be aware of paralysis occurred in three of 25 succinylcholine and eight of 94 pancuronium uses .", "spans": [{"span_id": 0, "text": "succinylcholine", "start": 83, "end": 98, "token_start": 15, "token_end": 15}, {"span_id": 1, "text": "pancuronium", "start": 115, "end": 126, "token_start": 20, "token_end": 20}], "rels": [], "paragraph": "Neuromuscular blockade for critical patients in the emergency department. This retrospective study examines the indications and the effects of 119 doses of succinylcholine or pancuronium given in the emergency department during a 24-month period to patients considered to have immediately life-threatening emergencies. The most common indication for succinylcholine was to accomplish tracheal intubation (20 of 25 patients). Indications for pancuronium included computerized tomography of the head (60 of 94), control of agitation (40 of 94), facilitation of tracheal intubation (20 of 94), control of ventilation (12 of 94), and control of seizure unresponsive to anticonvulsants (4 of 94). Deterioration following succinylcholine occurred in three cases. These included two involving bradycardia and one involving ventricular tachycardia. Major complications following pancuronium included four incidences of ventricular arrhythmias. Intubation failure requiring surgical airway occurred in one patient given succinylcholine, two patients given pancuronium, and one patient who received both succinylcholine and pancuronium. Inadequate documentation of neurological examination prior to blockade was noted in six of 25 succinylcholine and nine of 94 pancuronium cases. Failure to sedate patients who might be aware of paralysis occurred in three of 25 succinylcholine and eight of 94 pancuronium uses . Neuromuscular blocking agents facilitate expeditious management of selected critical patients in the ED. Their prudent use requires anticipation of potential complications, preparation for surgical airway should intubation fail, documentation of physical examination before paralysis, and prior sedation when the patient responds to pain."}
{"sentence": "Thirty-one isolates were classified as resistant to amprolium , 23 resistant to monensin , 10 resistant to diclazuril , and 6 resistant to clopidol .", "spans": [{"span_id": 0, "text": "amprolium", "start": 52, "end": 61, "token_start": 7, "token_end": 7}, {"span_id": 1, "text": "diclazuril", "start": 107, "end": 117, "token_start": 17, "token_end": 17}, {"span_id": 2, "text": "clopidol", "start": 139, "end": 147, "token_start": 23, "token_end": 23}], "rels": [], "paragraph": "Sensitivity of isolates of Eimeria from turkey flocks to the anticoccidial drugs amprolium, clopidol, diclazuril, and monensin. The sensitivity of field isolates of turkey coccidia from the United States to the anticoccidial drugs amprolium, clopidol, diclazuril, and monensin was investigated. clopidol and diclazuril were the most effective, followed by monensin and amprolium. Thirty-one isolates were classified as resistant to amprolium , 23 resistant to monensin , 10 resistant to diclazuril , and 6 resistant to clopidol . Six isolates were partially resistant to monensin, 10 partially resistant to clopidol, and 11 partially resistant to diclazuril. Four isolates were sensitive to monensin, 12 sensitive to diclazuril, and 17 sensitive to clopidol."}
{"sentence": "Approval was based on data from the APHINITY trial , which randomized patients to receive pertuzumab or placebo in combination with trastuzumab and chemotherapy .", "spans": [{"span_id": 0, "text": "pertuzumab", "start": 90, "end": 100, "token_start": 15, "token_end": 15}, {"span_id": 1, "text": "trastuzumab", "start": 132, "end": 143, "token_start": 21, "token_end": 21}], "rels": [], "paragraph": "FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer. On December 20, 2017, the FDA granted regular approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) at high risk of recurrence. Approval was based on data from the APHINITY trial , which randomized patients to receive pertuzumab or placebo in combination with trastuzumab and chemotherapy . After 45.4-month median follow-up, the proportion of invasive disease-free survival (IDFS) events in the intent-to-treat population was 7.1% ("}
{"sentence": "Thirteen patients with interstitial cystitis diagnosed by the NIH criteria were treated with intravesical electromotive administration of lidocaine and dexamethasone followed by cystodistention .", "spans": [{"span_id": 0, "text": "lidocaine", "start": 138, "end": 147, "token_start": 17, "token_end": 17}, {"span_id": 1, "text": "dexamethasone", "start": 152, "end": 165, "token_start": 19, "token_end": 19}, {"span_id": 2, "text": "cystodistention", "start": 178, "end": 193, "token_start": 22, "token_end": 22}], "rels": [{"class": "POS", "spans": [0, 1, 2]}], "paragraph": "Electromotive drug administration and hydrodistention for the treatment of interstitial cystitis.  Thirteen patients with interstitial cystitis diagnosed by the NIH criteria were treated with intravesical electromotive administration of lidocaine and dexamethasone followed by cystodistention . After a mean follow-up of 10 (range 3-22) months, 8/13 (62%) of the patients reported complete resolution of bladder symptoms lasting an average 4.5 (range 0.75-17) months. Partial or short-term improvement of bladder symptoms was observed in three patients, while two patients reported aggravation of pain for several days after therapy. A significant increase in bladder capacity, to an average 166% of the pretreatment capacity, was observed in all patients. Whenever symptoms recurred after initially effective therapy, retreatments were performed with equal efficacy in 11 patients. This promising new therapeutic approach, performed on an outpatient basis, may become first-line treatment for patients with interstitial cystitis."}
{"sentence": "Drug therapy included omega-3 fish oil , extended-release niacin , colesevelam hydrochloride , and a fixed combination of 10-mg ezetimibe and 40-mg simvastatin .", "spans": [{"span_id": 0, "text": "omega-3", "start": 22, "end": 29, "token_start": 3, "token_end": 3}, {"span_id": 1, "text": "niacin", "start": 58, "end": 64, "token_start": 8, "token_end": 8}, {"span_id": 2, "text": "colesevelam hydrochloride", "start": 67, "end": 92, "token_start": 10, "token_end": 11}, {"span_id": 3, "text": "ezetimibe", "start": 128, "end": 137, "token_start": 19, "token_end": 19}, {"span_id": 4, "text": "simvastatin", "start": 148, "end": 159, "token_start": 22, "token_end": 22}], "rels": [{"class": "POS", "spans": [0, 1, 2, 3, 4]}], "paragraph": "Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy. Lipoprotein-associated phospholipase A2 (Lp-PLA(2)) mass is a novel inflammatory biomarker. In human blood, Lp-PLA(2) is predominately associated with low-density lipoprotein (LDL). This study examines the ability of lifestyle modification (diet and exercise) and combination lipid therapy to reduce Lp-PLA(2) levels while also determining the relationship between changes in LDL cholesterol and Lp-PLA(2). Thirty dyslipidemic patients who received lifestyle intervention and combination lipid therapy for an average of 6 months were included in these analyses (mean age, 60.9 years); 40% had stable angiographically established coronary artery disease, 40% had the metabolic syndrome, and 70% were men. Drug therapy included omega-3 fish oil , extended-release niacin , colesevelam hydrochloride , and a fixed combination of 10-mg ezetimibe and 40-mg simvastatin . The study revealed a 33% reduction in mean Lp-PLA(2) values (baseline 224.9+/-47.5 vs posttreatment 149.5+/-35.5 ng/mL; P<.001). Significant changes in mean LDL cholesterol from baseline (127.9+/-49.3 vs posttreatment 65.2+/-32.1 mg/dL; P<.001) were also observed. However, regression analysis revealed only a weak positive relationship between changes in LDL cholesterol and Lp-PLA(2) mass (R(2)=0.29; P<.01). Thus, Lp-PLA(2) mass is significantly reduced with lifestyle and combination lipid therapy. Changes in Lp-PLA(2) were only partially explained by the changes observed for LDL cholesterol."}
{"sentence": "Twenty-one Japanese colorectal cancer patients received intravenous FOLFIRI ( bolus irinotecan , folinic acid , and fluorouracil followed by 46-hour fluorouracil infusion ) followed by bevacizumab ( 5 mg/kg ) in Cycle 1 .", "spans": [{"span_id": 0, "text": "irinotecan", "start": 84, "end": 94, "token_start": 10, "token_end": 10}, {"span_id": 1, "text": "folinic acid", "start": 97, "end": 109, "token_start": 12, "token_end": 13}, {"span_id": 2, "text": "fluorouracil", "start": 116, "end": 128, "token_start": 16, "token_end": 16}, {"span_id": 3, "text": "fluorouracil", "start": 149, "end": 161, "token_start": 20, "token_end": 20}, {"span_id": 4, "text": "bevacizumab", "start": 185, "end": 196, "token_start": 25, "token_end": 25}], "rels": [{"class": "COMB", "spans": [0, 1, 2, 3, 4]}], "paragraph": "Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. Previous reports of the influence of UGT1A1 gene polymorphisms on the pharmacokinetics of irinotecan metabolism have not assessed Asian patients treated with FOLFIRI plus bevacizumab for advanced and recurrent colorectal cancer. Twenty-one Japanese colorectal cancer patients received intravenous FOLFIRI ( bolus irinotecan , folinic acid , and fluorouracil followed by 46-hour fluorouracil infusion ) followed by bevacizumab ( 5 mg/kg ) in Cycle 1 . In Cycle 2, patients received bevacizumab followed by FOLFIRI. The regimen was in 2-week cycles. The area under-the-curves ratio (AUC0-last) (Cycle 2/Cycle 1) was determined from plasma concentrations of irinotecan and metabolites (SN-38, SN-38G). Safety, efficacy, and drug-drug interactions were analyzed. Median observation period was 7.8 months; median number of cycles 15. Drug-drug interactions were evaluated in eight patients without irinotecan dose reduction. Mean AUC0-last ratios (with/without bevacizumab) of irinotecan, SN-38, and SN-38G were 0.959, 0.927, and 0.931 respectively. Response rate was 65%; median progression-free survival 16.4 months. Response occurred in four patients with, and nine without, UGT1A1 polymorphism. No significant differences occurred between efficacy, safety, or polymorphism status. This cohort showed no differences in safety or efficacy compared to previous reports. bevacizumab did not affect the pharmacokinetics of irinotecan and its metabolites, irrespective of UGT1A1 polymorphism status. "}
{"sentence": "Patients received vinorelbine starting at 20 mg/m(2 ) ( to 25 mg/m(2 ) ) and carboplatin area under the curve ( AUC ) 2.5 in divided-doses , both given on Days 1 and 8 every 21-day cycle for up to 6 cycles or until disease progression .", "spans": [{"span_id": 0, "text": "vinorelbine", "start": 18, "end": 29, "token_start": 2, "token_end": 2}, {"span_id": 1, "text": "carboplatin", "start": 77, "end": 88, "token_start": 15, "token_end": 15}], "rels": [{"class": "POS", "spans": [0, 1]}], "paragraph": "Phase I/II trial of vinorelbine and divided-dose carboplatin in advanced non-small cell lung cancer. vinorelbine administered in a doublet with cisplatin has become a standard treatment in patients with advanced non-small cell lung cancer (NSCLC). However, carboplatin appears to provide comparable efficacy with a better nonhematologic safety profile than cisplatin. Herein we report the results of a phase I/II trial of weekly vinorelbine and divided-dose carboplatin in patients with stage IIIB/IV NSCLC, Eastern Cooperative Oncology Group performance status < or = 2, and adequate bone marrow. Patients received vinorelbine starting at 20 mg/m(2 ) ( to 25 mg/m(2 ) ) and carboplatin area under the curve ( AUC ) 2.5 in divided-doses , both given on Days 1 and 8 every 21-day cycle for up to 6 cycles or until disease progression . Dose-limiting toxicity was defined for Cycles 1 and 2. Tumor response and toxicity were assessed using standard criteria. Twenty-one patients with a mean age of 67 years (range, 43-79) and stage IIIB/IV (8/13) disease were enrolled. All but 1 patient were chemotherapy-nai;ve; the majority (n = 20) had good performance status (< or = 1). Seventy-nine courses (median, 4) were administered. The vinorelbine/carboplatin doublet was well tolerated, with 7 courses interrupted or delayed because of toxicity. Toxicities were generally mild and evenly divided between hematologic (i.e., neutropenia) and nonhematologic (i.e., fatigue). No growth factor support was required for hematologic toxicity. There was only one case of grade 2 alopecia, and no cases of > or = grade 2 neurotoxicity. There were 5 (24%) partial responses, and 9 (43%) patients had stable disease. Weekly vinorelbine 25 mg/m(2) and divided-dose carboplatin AUC 2.5 is a well tolerated regimen with activity in advanced NSCLC patients. Further evaluation of this regimen in combination with novel targeted biologic therapy is warranted."}
{"sentence": "Dexamethasone exhibited the highest effect on paclitaxel anti-tumor activity , in a dose-dependent fashion .", "spans": [{"span_id": 0, "text": "Dexamethasone", "start": 0, "end": 13, "token_start": 0, "token_end": 0}, {"span_id": 1, "text": "paclitaxel", "start": 46, "end": 56, "token_start": 6, "token_end": 6}], "rels": [{"class": "COMB", "spans": [0, 1]}], "paragraph": "Efficacy of paclitaxel/dexamethasone intra-tumoral delivery in treating orthotopic mouse breast cancer. The effect of topical co-administration of promoter drugs with paclitaxel to increase anti-tumor effects of paclitaxel was investigated. Mice with orthotopic 4T1-Luc breast cancer received single intra-tumoral injection of a polymeric formulation with paclitaxel and a specific promoter drug. Several promoter drugs were evaluated, including: dexamethasone, losartan, nicotinamide, Azone, and oleic acid. Dexamethasone exhibited the highest effect on paclitaxel anti-tumor activity , in a dose-dependent fashion . However, this effect was accompanied by systemic effects of dexamethasone, and inability to prevent tumor metastasis to the lungs. Topical co-administration of promoter drugs with anti-cancer agents can enhance their anti-tumor effects. Further investigations are needed to identify the most efficient combinations of promoter and anti-cancer drugs, and their suitability for the clinical management of the breast cancer disease."}
{"sentence": "The first available studies demonstrate the value of these compounds with an improved prognosis of metastatic patients in combination with endocrine therapy ( palbociclib , ribociclib ) or in monotherapy ( abemaciclib ) .", "spans": [{"span_id": 0, "text": "palbociclib", "start": 159, "end": 170, "token_start": 23, "token_end": 23}, {"span_id": 1, "text": "ribociclib", "start": 173, "end": 183, "token_start": 25, "token_end": 25}, {"span_id": 2, "text": "abemaciclib", "start": 206, "end": 217, "token_start": 31, "token_end": 31}], "rels": [], "paragraph": "[Cell cycle inhibitors in endocrine receptor positive breast cancer]. Dysregulation of cellular cycle is a key component of carcinogenesis and its targeting represents an interesting approach. Recently, the development of selective inhibitors of the cycle targeting the cyclin-dependent kinases (CDK) 4\u00a0and 6\u00a0revived interest in this therapeutic class after the failure of pan-inhibitors. palbociclib, ribociclib, and abemaciclib are the 3\u00a0drugs with the most advanced development. They demonstrated preclinical activity in luminal breast cancer models and are under clinical evaluation. The first available studies demonstrate the value of these compounds with an improved prognosis of metastatic patients in combination with endocrine therapy ( palbociclib , ribociclib ) or in monotherapy ( abemaciclib ) . The results of ongoing studies will clarify the role of these agents in our new strategies and the individualisation of biomarkers will help to define patients who benefit most from this approach."}
{"sentence": "Flunarizine pretreatment abolished the augmented behavioral response to repeated cocaine administration while diltiazem was less effective .", "spans": [{"span_id": 0, "text": "Flunarizine", "start": 0, "end": 11, "token_start": 0, "token_end": 0}, {"span_id": 1, "text": "diltiazem", "start": 110, "end": 119, "token_start": 12, "token_end": 12}], "rels": [], "paragraph": "Augmented behavioral response and enhanced synaptosomal calcium transport induced by repeated cocaine administration are decreased by calcium channel blockers. Recent studies suggest that calcium influx via L-type calcium channels is necessary for psychostimulant-induced behavioral sensitization. In addition, chronic amphetamine upregulates subtype Cav1.2-containing L-type calcium channels. In the present studies, we assessed the effect of calcium channel blockers (CCBs) on cocaine-induced behavioral sensitization and determined whether the functional activity of L-type calcium channels is altered after repeated cocaine administration. Rats were administered daily intraperitoneal injections of either flunarizine (40 mg/kg), diltiazem (40 mg/kg) or cocaine (20 mg/kg) and the combination of the CCBs and cocaine for 30 days. Motor activities were monitored on Day 1, and every 6th day during the 30-day treatment period. Daily cocaine administration produced increased locomotor activity. Maximal augmentation of behavioral response to repeated cocaine administration was observed on Day 18. Flunarizine pretreatment abolished the augmented behavioral response to repeated cocaine administration while diltiazem was less effective . Measurement of tissue monoamine levels on Day 18 revealed cocaine-induced increases in DA and 5-HT in the nucleus accumbens. By contrast to behavioral response, diltiazem was more effective in attenuating increases in monoamine levels than flunarizine. Cocaine administration for 18 days produced increases in calcium uptake in synaptosomes prepared from the nucleus accumbens and frontal cortex. Increases in calcium uptake were abolished by flunarizine and diltiazem pretreatment. Taken together, the augmented cocaine-induced behavioral response on Day 18 may be due to increased calcium uptake in the nucleus accumbens leading to increased dopamine (DA) and serotonin (5-HT) release. flunarizine and diltiazem attenuated the behavioral response by decreasing calcium uptake and decreasing neurochemical release."}
{"sentence": "We therefore explored the in vitro combination of amphotericin B with itraconazole against 14 clinical Aspergillus fumigatus isolates ( 9 itraconazole susceptible and 5 itraconazole resistant ) with a colorimetric broth microdilution checkerboard technique using two drug interaction models able to explore complicated patterns of interactions : the response surface analysis of Bliss independence and the isobolographic analysis of Loewe additivity zero interaction theories .", "spans": [{"span_id": 0, "text": "amphotericin", "start": 50, "end": 62, "token_start": 8, "token_end": 8}, {"span_id": 1, "text": "itraconazole", "start": 70, "end": 82, "token_start": 11, "token_end": 11}, {"span_id": 2, "text": "itraconazole", "start": 138, "end": 150, "token_start": 20, "token_end": 20}, {"span_id": 3, "text": "itraconazole", "start": 169, "end": 181, "token_start": 24, "token_end": 24}], "rels": [{"class": "POS", "spans": [0, 1]}], "paragraph": "The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions. The interaction between polyenes and azoles is not well understood. We therefore explored the in vitro combination of amphotericin B with itraconazole against 14 clinical Aspergillus fumigatus isolates ( 9 itraconazole susceptible and 5 itraconazole resistant ) with a colorimetric broth microdilution checkerboard technique using two drug interaction models able to explore complicated patterns of interactions : the response surface analysis of Bliss independence and the isobolographic analysis of Loewe additivity zero interaction theories . Synergy was found at combinations with low concentrations of amphotericin B (<0.125 mg/L), whereas antagonism was found at combinations with higher concentrations of amphotericin B. For itraconazole-resistant isolates, synergistic interactions were observed at high concentrations of itraconazole (>0.5 mg/L). Synergy was more frequently observed for the itraconazole-resistant isolates than for the itraconazole-susceptible isolates."}
{"sentence": "This study evaluated the safety and efficacy of inotuzumab ozogamicin ( INO ) , a targeted humanized anti-CD22 antibody conjugated to calicheamicin , plus rituximab ( R-INO ) every 3 weeks , up to six cycles , followed by high dose therapy and autologous stem cell transplant ( HDT-aSCT ) in patients with high-risk relapsed/refractory diffuse large B-cell lymphoma ( DLBCL ) .", "spans": [{"span_id": 0, "text": "inotuzumab", "start": 48, "end": 58, "token_start": 8, "token_end": 8}, {"span_id": 1, "text": "ozogamicin", "start": 59, "end": 69, "token_start": 9, "token_end": 9}, {"span_id": 2, "text": "rituximab", "start": 155, "end": 164, "token_start": 24, "token_end": 24}, {"span_id": 3, "text": "HDT-aSCT", "start": 278, "end": 286, "token_start": 48, "token_end": 48}], "rels": [{"class": "COMB", "spans": [0, 2, 3]}], "paragraph": "A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.  This study evaluated the safety and efficacy of inotuzumab ozogamicin ( INO ) , a targeted humanized anti-CD22 antibody conjugated to calicheamicin , plus rituximab ( R-INO ) every 3 weeks , up to six cycles , followed by high dose therapy and autologous stem cell transplant ( HDT-aSCT ) in patients with high-risk relapsed/refractory diffuse large B-cell lymphoma ( DLBCL ) . The primary endpoint was overall response (OR) rate after three cycles of R-INO. Sixty-three patients were enrolled. Common grade 3/4 adverse events during R-INO treatment were thrombocytopenia, lymphopenia and neutropenia. OR rate after three cycles of R-INO was 28.6% (95% confidence interval: 17.9-41.4). Eighteen patients underwent HDT-aSCT; 2-year progression-free survival (PFS) for these patients was 61.1%. Serious infections and hepatic toxicity following aSCT occurred in 33% and 22%, respectively. One- and 2-year PFS rates for all enrolled patients were 28.9% and 25.3%, respectively (median, 3.0 months). R-INO had lower than expected activity as a salvage regimen for transplant eligible patients with DLBCL. "}
{"sentence": "These are the first 2 reports of successful treatment of this condition by use of a combination of methylprednisolone and mycophenolate mofetil , and , in 1 of the cases , additional medication with intravenous immunoglobulin .", "spans": [{"span_id": 0, "text": "methylprednisolone", "start": 99, "end": 117, "token_start": 18, "token_end": 18}, {"span_id": 1, "text": "mycophenolate", "start": 122, "end": 135, "token_start": 20, "token_end": 20}, {"span_id": 2, "text": "immunoglobulin", "start": 211, "end": 225, "token_start": 35, "token_end": 35}], "rels": [{"class": "POS", "spans": [0, 1]}, {"class": "POS", "spans": [0, 1, 2]}], "paragraph": "Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases. ipilimumab binds and blocks cytotoxic T-lymphocyte-associated antigen-4, causing enhanced T-cell reaction, antitumor response, and significant improvement of the overall survival of patients with metastatic melanoma. Patients treated with ipilimumab can develop immune-related adverse effects, primarily dermatitis, colitis, hepatitis, and hypophysitis. Although, in phase I-III studies, 64.2% of all patients suffered from immune-related adverse effects, ocular adverse effects occurred in 1.3% only. In the cases reported below, 2 patients with metastatic melanoma developed severe ocular myositis after treatment with ipilimumab. These are the first 2 reports of successful treatment of this condition by use of a combination of methylprednisolone and mycophenolate mofetil , and , in 1 of the cases , additional medication with intravenous immunoglobulin ."}
{"sentence": "The introduction of the selective serotonin reuptake inhibitors , moclobemide and mianserin has been a major advance in the treatment of depression , and is already leading to major shifts in the pattern of antidepressants prescribing .", "spans": [{"span_id": 0, "text": "moclobemide", "start": 66, "end": 77, "token_start": 9, "token_end": 9}, {"span_id": 1, "text": "mianserin", "start": 82, "end": 91, "token_start": 11, "token_end": 11}], "rels": [], "paragraph": "The management of depression. The place of the new antidepressants. Part 1. General overview.  The introduction of the selective serotonin reuptake inhibitors , moclobemide and mianserin has been a major advance in the treatment of depression , and is already leading to major shifts in the pattern of antidepressants prescribing . These antidepressants are safe, well tolerated and effective, and in conjunction with older agents such as the tricyclics, provide the clinician with a broad range of treatments for this common and disabling disorder. This two-part review will focus on the management of depression in general practice."}
{"sentence": "Topotecan , a semisynthetic camptothecin , exerts its cytotoxic effect through inhibition of DNA topoisomerase I. Single-agent topotecan has demonstrated activity against persistent , metastatic and recurrent cancer of the uterine cervix .", "spans": [{"span_id": 0, "text": "Topotecan", "start": 0, "end": 9, "token_start": 0, "token_end": 0}, {"span_id": 1, "text": "topotecan", "start": 127, "end": 136, "token_start": 17, "token_end": 17}], "rels": [], "paragraph": "Topotecan in the management of cervical cancer.  Topotecan , a semisynthetic camptothecin , exerts its cytotoxic effect through inhibition of DNA topoisomerase I. Single-agent topotecan has demonstrated activity against persistent , metastatic and recurrent cancer of the uterine cervix . When combined with cisplatin in Phase II trials, further improved response rates have been reported. The cisplatin/topotecan doublet subsequently proved to be the first regimen in a series of multiple Phase III studies to demonstrate improved disease-free and overall survival in this setting compared with cisplatin alone, thus leading to its third indication by both the US FDA and the European Medicines Agency in 2006. This survival advantage was achieved at the expense of an increase in grade 3-4 hematologic toxicity; however, there was no difference in patient-reported quality of life between the cisplatin/topotecan doublet and single-agent cisplatin. This article reviews the pharmacology of topotecan and its evolution as an active agent in advanced and metastatic cervical cancer that is not amenable to cure with surgery or radiotherapy."}
{"sentence": "Four of these had equivocal plasma levels of both norepinephrine and epinephrine , suggesting that overnight clonidine suppression may be of particular value when tumor secretion is intermittent or low .", "spans": [{"span_id": 0, "text": "epinephrine", "start": 69, "end": 80, "token_start": 11, "token_end": 11}, {"span_id": 1, "text": "clonidine", "start": 109, "end": 118, "token_start": 16, "token_end": 16}], "rels": [], "paragraph": "Overnight clonidine suppression test in the diagnosis and exclusion of pheochromocytoma. In a prospective study designed to differentiate pheochromocytoma from other forms of hypertension, urinary catecholamines were measured after sleep and clonidine administration in 12 patients with pheochromocytoma, 19 hypertensive patients in whom pheochromocytoma was suspected but later excluded, and 31 hypertensive patients in whom pheochromocytoma was never suspected. The test correctly identified all 12 patients in whom pheochromocytoma was present. Four of these had equivocal plasma levels of both norepinephrine and epinephrine , suggesting that overnight clonidine suppression may be of particular value when tumor secretion is intermittent or low . When pheochromocytoma was not present, urinary norepinephrine and epinephrine levels were suppressed below 60 and 20 nmol/mmol creatinine, respectively, after sleep and clonidine, the two in combination giving better suppression than sleep alone. Since urinary catecholamines can be determined relatively easily by high-pressure liquid chromatography with electrochemical detection, this test may be more widely applicable than suppression tests based on plasma measurements."}
{"sentence": "In conclusion , concurrent introduction of ATGAM and tacrolimus is a promising therapeutic combination for GVHD refractory to steroids and cyclosporine .", "spans": [{"span_id": 0, "text": "ATGAM", "start": 43, "end": 48, "token_start": 6, "token_end": 6}, {"span_id": 1, "text": "tacrolimus", "start": 53, "end": 63, "token_start": 8, "token_end": 8}, {"span_id": 2, "text": "steroids", "start": 126, "end": 134, "token_start": 18, "token_end": 18}, {"span_id": 3, "text": "cyclosporine", "start": 139, "end": 151, "token_start": 20, "token_end": 20}], "rels": [{"class": "POS", "spans": [0, 1]}], "paragraph": "Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis. We report our experience with the combination of anti-thymocyte globulin (ATGAM) and tacrolimus in the treatment of 20 patients with steroid refractory and dependent acute graft-versus-host disease (GVHD) transplanted between August 1996 and February 2000. All patients received cyclosporine-based GVHD prophylaxis. Thirteen patients developed a maximum of grade IV, five grade III and two grade II acute GVHD, with 15 patients being refractory to steroids and five dependent on steroids. Patients were treated with ATGAM (15 mg/kg for 5 d) and tacrolimus (0.025--0.1 mg/kg/d) in addition to continuation of their high-dose steroids and cessation of their cyclosporine. Within 28 d of treatment, we observed eight complete responses (CR), six partial responses (PR) and six with no response. Overall response (CR + PR) was predicted by GVHD severity. Infectious complications occurred in 80% of patients. The median survival was 86.5 d (range, 21--1081 d) with 35% of patients remaining alive. Survival following combination therapy was significantly more likely in men (P < 0.001), skin-only GVHD (P = 0.027), less severe GVHD (P = 0.048), and in responders to tacrolimus and ATGAM (P < 0.001). In conclusion , concurrent introduction of ATGAM and tacrolimus is a promising therapeutic combination for GVHD refractory to steroids and cyclosporine ."}
{"sentence": "Comparison of geometric least-squares mean PK parameters between arms showed no impact of pertuzumab on the PK of trastuzumab or docetaxel .", "spans": [{"span_id": 0, "text": "pertuzumab", "start": 90, "end": 100, "token_start": 13, "token_end": 13}, {"span_id": 1, "text": "trastuzumab", "start": 114, "end": 125, "token_start": 18, "token_end": 18}, {"span_id": 2, "text": "docetaxel", "start": 129, "end": 138, "token_start": 20, "token_end": 20}], "rels": [{"class": "COMB", "spans": [0, 1]}, {"class": "COMB", "spans": [0, 2]}], "paragraph": "Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. pertuzumab is a novel antihuman epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody. Combined with trastuzumab plus docetaxel, pertuzumab improved progression-free and overall survival versus trastuzumab plus docetaxel in the phase III CLEOPATRA trial (NCT00567190) in first-line HER2-positive metastatic breast cancer. Thirty-seven patients participated in a pharmacokinetic (PK)/corrected QT interval substudy of CLEOPATRA, which evaluated potential PK drug-drug interaction (DDI). PK parameters were calculated using noncompartmental methods, and DDI analyses were carried out. In the presence of trastuzumab and docetaxel, the mean pertuzumab Cmin and Cmax in cycle 3 were 63.6 and 183 \u00b5g/ml, respectively. The pertuzumab concentrations observed were consistent with simulations from a validated population PK model, indicating that trastuzumab and docetaxel did not alter pertuzumab PK. Comparison of geometric least-squares mean PK parameters between arms showed no impact of pertuzumab on the PK of trastuzumab or docetaxel . In conclusion, no PK DDI was observed when pertuzumab, trastuzumab, and docetaxel were combined for the treatment of HER2-positive metastatic breast cancer. "}
{"sentence": "This study was designed to test the hypothesis that positively charged dendrimers form a complex with enoxaparin , a low-molecular weight heparin ( LMWH ) , and that the resulting drug-dendrimer complex is effective in preventing deep vein thrombosis after pulmonary administration .", "spans": [{"span_id": 0, "text": "enoxaparin", "start": 102, "end": 112, "token_start": 16, "token_end": 16}, {"span_id": 1, "text": "heparin", "start": 138, "end": 145, "token_start": 21, "token_end": 21}], "rels": [], "paragraph": "Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin.  This study was designed to test the hypothesis that positively charged dendrimers form a complex with enoxaparin , a low-molecular weight heparin ( LMWH ) , and that the resulting drug-dendrimer complex is effective in preventing deep vein thrombosis after pulmonary administration . Fourier Transform Infrared (FTIR) spectroscopy and the azure A assay were used to evaluate interactions between dendrimers and enoxaparin. The efficacy of polyamidoamine (PAMAM) dendrimers in enhancing pulmonary absorption of enoxaparin was studied by administering enoxaparin-dendrimer formulations into the lungs of anesthetized rats and monitoring drug absorption by measuring plasma anti-factor Xa activity. The optimized formulations were evaluated for their efficacy in preventing deep vein thrombosis in a rodent model. The safety of the formulations was tested by studying their effects on mucociliary transport rate (MTR) in a frog palate model and by measuring injury markers in rat bronchoalveolar fluid. The FTIR data and azure A assay revealed ionic interactions between the amino groups of cationic dendrimers and the carboxylic and sulfate groups of enoxaparin. Positively charged dendrimers increased the relative bioavailability of enoxaparin by 40%, while a negatively charged dendrimer had no effect. Formulations containing 1% G2 or 0.5% G3 PAMAM dendrimer plus enoxaparin were as efficacious in preventing deep vein thrombosis in a rat model as subcutaneously administered enoxaparin. The formulations did not adversely affect the MTR or produce extensive damage to the lungs. Positively charged dendrimers are a suitable carrier for pulmonary delivery of enoxaparin. They enhance pulmonary absorption of LMWH probably by reducing negative surface charge density of the drug molecule."}
{"sentence": "We proved experimentally the use of ECEEM for multiplex determination of kinetic parameters describing weak ( 3 mM > K(d ) > 80 \u03bcM ) and fast ( 0.25 s \u2265 \u03c4 \u2265 0.9 ms ) noncovalent interactions between four small molecule drugs ( ibuprofen , S-flurbiprofen , salicylic acid and phenylbutazone ) and \u03b1- and \u03b2-cyclodextrins .", "spans": [{"span_id": 0, "text": "ibuprofen", "start": 227, "end": 236, "token_start": 44, "token_end": 44}, {"span_id": 1, "text": "S-flurbiprofen", "start": 239, "end": 253, "token_start": 46, "token_end": 46}, {"span_id": 2, "text": "salicylic acid", "start": 256, "end": 270, "token_start": 48, "token_end": 49}, {"span_id": 3, "text": "phenylbutazone", "start": 275, "end": 289, "token_start": 51, "token_end": 51}, {"span_id": 4, "text": "\u03b2-cyclodextrins", "start": 303, "end": 318, "token_start": 56, "token_end": 56}], "rels": [{"class": "COMB", "spans": [0, 4]}, {"class": "COMB", "spans": [1, 4]}, {"class": "COMB", "spans": [3, 4]}], "paragraph": "Revealing equilibrium and rate constants of weak and fast noncovalent interactions. Rate and equilibrium constants of weak noncovalent molecular interactions are extremely difficult to measure. Here, we introduced a homogeneous approach called equilibrium capillary electrophoresis of equilibrium mixtures (ECEEM) to determine k(on), k(off), and K(d) of weak (K(d) > 1 \u03bcM) and fast kinetics (relaxation time, \u03c4 < 0.1 s) in quasi-equilibrium for multiple unlabeled ligands simultaneously in one microreactor. Conceptually, an equilibrium mixture (EM) of a ligand (L), target (T), and a complex (C) is prepared. The mixture is introduced into the beginning of a capillary reactor with aspect ratio >1000 filled with T. Afterward, differential mobility of L, T, and C along the reactor is induced by an electric field. The combination of differential mobility of reactants and their interactions leads to a change of the EM peak shape. This change is a function of rate constants, so the rate and equilibrium constants can be directly determined from the analysis of the EM peak shape (width and symmetry) and propagation pattern along the reactor. We proved experimentally the use of ECEEM for multiplex determination of kinetic parameters describing weak ( 3 mM > K(d ) > 80 \u03bcM ) and fast ( 0.25 s \u2265 \u03c4 \u2265 0.9 ms ) noncovalent interactions between four small molecule drugs ( ibuprofen , S-flurbiprofen , salicylic acid and phenylbutazone ) and \u03b1- and \u03b2-cyclodextrins . The affinity of the drugs was significantly higher for \u03b2-cyclodextrin than \u03b1-cyclodextrin and mostly determined by the rate constant of complex formation."}
{"sentence": "We evaluated the stem cell mobilization regimen of high-dose ifosfamide plus etoposide in 32 patients with epithelial ovarian cancer , who had a positive second-look laparatomy or recurrent disease .", "spans": [{"span_id": 0, "text": "ifosfamide", "start": 61, "end": 71, "token_start": 9, "token_end": 9}, {"span_id": 1, "text": "etoposide", "start": 77, "end": 86, "token_start": 11, "token_end": 11}], "rels": [{"class": "COMB", "spans": [0, 1]}], "paragraph": "High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. High-dose chemotherapy combined with autologous peripheral blood stem cell transplantation has shown promise as treatment for recurrent or persistent epithelial ovarian cancer. We evaluated the stem cell mobilization regimen of high-dose ifosfamide plus etoposide in 32 patients with epithelial ovarian cancer , who had a positive second-look laparatomy or recurrent disease . ifosfamide was given at 10 g/m2 by continuous i.v. from days 1 to 3. etoposide was given at 150 mg/m2 every 12 h for six doses on days 1-3. filgrastim was given at 10 microg/kg/d s.c. from day 5 until the completion of peripheral blood stem cell harvest. Fourteen of 32 patients had measurable or evaluable disease before mobilization therapy and were assessed for response. In nine (64%) of the 14 patients, treatment response was demonstrated, and these patients received a second cycle of mobilization therapy. The target CD34+ cell dose (>8 x 106 cells/kg) was achieved with a median of one apheresis (range 1-5). A median of 25.1 (range 8.0-122.5) x 106 CD34+ cells/kg body weight was collected. Non-hematologic toxicity was limited to grade 2 renal dysfunction in one patient and grade 2 hepatic dysfunction in three patients. In this patient group, high-dose ifosfamide plus etoposide with filgrastim support was well tolerated, lead to successful stem cell harvest and had antitumor activity."}
{"sentence": "Esomeprazole , a proton-pump inhibitor ( PPI ) , is the S-isomer of omeprazole .", "spans": [{"span_id": 0, "text": "Esomeprazole", "start": 0, "end": 12, "token_start": 0, "token_end": 0}, {"span_id": 1, "text": "omeprazole", "start": 68, "end": 78, "token_start": 13, "token_end": 13}], "rels": [], "paragraph": "Esomeprazole: a clinical review. The pharmacology, pharmacodynamics, pharmacokinetics, clinical efficacy, and adverse effects of esomeprazole are reviewed. Esomeprazole , a proton-pump inhibitor ( PPI ) , is the S-isomer of omeprazole . esomeprazole has FDA-approved labeling for use in the treatment of symptomatic gastroesophageal reflux disease (GERD), including healing and maintenance of healing of erosive esophagitis and as part of a triple-drug regimen for Helicobocter pylori infection. esomeprazole is structurally similar to other PPIs but is the first PPI to include only the active isomer, which may lead to improved pharmacokinetic and pharmacodynamic characteristics. esomeprazole maintains intragastric pH at a higher level and above 4 for a longer period than other PPIs. Clinical studies have shown that esomeprazole is at least equivalent in safety and efficacy to other drugs in the class. esomeprazole has demonstrated efficacy in the treatment of erosive esophagitis, the maintenance of healing of erosive esophagitis, and the treatment of signs and symptoms of GERD. Effective dosages are 20 or 40 mg orally every day or as needed. esomeprazole magnesium 40 mg once daily in combination with amoxicillin and clarithromycin is effective in eradicating H. pylori infection. The potential for interacting with other drugs is limited and is similar to that of omeprazole. The most common adverse effects are headache, respiratory infection, and abdominal symptoms. esomeprazole has pharmacokinetic properties that may make it more effective than omeprazole in some patients."}
{"sentence": "This increase in the number of vasopressin and oxytocin containing neurons in the pig hypothalamus is much later in development than has ever been reported so far .", "spans": [{"span_id": 0, "text": "vasopressin", "start": 31, "end": 42, "token_start": 6, "token_end": 6}, {"span_id": 1, "text": "oxytocin", "start": 47, "end": 55, "token_start": 8, "token_end": 8}], "rels": [], "paragraph": "A vasopressin and oxytocin containing nucleus in the pig hypothalamus that shows neuronal changes during puberty. A vasopressin and oxytocin containing nucleus is described for the first time in the pig hypothalamus. It is located near the third ventricle, just dorsal to the suprachiasmatic nucleus, and consists of magnocellular neurons, similar to those of the supraoptic nucleus and paraventricular nucleus. Morphometric analysis of neuronal number, size, density, and volume was performed at four different ages: 1 day, 7 weeks, 16 weeks, and 30 weeks postnatally. No sex difference in these parameters was observed. In this period the volume of the nucleus increased gradually from 6.6 x 10(-3) to 54.2 x 10(-3) mm3. One day after birth 1,215 +/- 191 (mean +/- SEM) neurons were present in the vasopressin and oxytocin containing nucleus, followed by a decrease to 771 +/- 80 neurons at 7 weeks and 697 +/- 116 at 16 weeks. Between 16 and 30 weeks (puberty) there was a dramatic increase in neuron number up to 1,765 +/- 214 neurons. This increase in the number of vasopressin and oxytocin containing neurons in the pig hypothalamus is much later in development than has ever been reported so far ."}
{"sentence": "Combinations of alkylating agents and fludarabine or cladribine are also synergistic in producing significantly enhanced activity against refractory lymphoid malignancies , but at the cost of increased haematological toxicity .", "spans": [{"span_id": 0, "text": "alkylating agents", "start": 16, "end": 33, "token_start": 2, "token_end": 3}, {"span_id": 1, "text": "fludarabine", "start": 38, "end": 49, "token_start": 5, "token_end": 5}, {"span_id": 2, "text": "cladribine", "start": 53, "end": 63, "token_start": 7, "token_end": 7}], "rels": [{"class": "COMB", "spans": [0, 1]}, {"class": "COMB", "spans": [0, 2]}], "paragraph": "Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies. This review establishes the pharmacokinetic characteristics of the major nucleoside analogues with cytotoxic activity. cytarabine, pentostatin, fludarabine, cladribine and gemcitabine are all prodrugs whose plasma pharmacokinetics do not fully reflect their therapeutic activity; after cellular uptake, these compounds undergo phosphorylation by deoxycytidine kinase before their incorporation into DNA results in cell death. cytarabine is principally active in the S phase of the cell cycle and is most toxic to replicating cells, whereas pentostatin, fludarabine and cladribine are incorporated into DNA during the process in which strand breaks are repaired and are therefore cytotoxic to slowly replicating cells (although the action of pentostatin results from its inhibition of adenosine deaminase). gemcitabine is unusual in being highly metabolised in solid tumour cells. The cytotoxic activity of pentostatin, fludarabine and cladribine against the clonal cells of lymphoproliferative disorders is accompanied by damage to normal lymphoid cells, which results in significant and long-lasting immunosuppression. Useful interactions between nucleoside analogues have been defined. Cells that are primed by exposure to fludarabine or cladribine exhibit enhanced accumulation of cytarabine triphosphate (the cytotoxic nucleotide of cytarabine) and an improved therapeutic effect against acute myeloid leukaemia and chronic lymphocytic leukaemia can be achieved by clinical schedules that exploit this effect. Combinations of alkylating agents and fludarabine or cladribine are also synergistic in producing significantly enhanced activity against refractory lymphoid malignancies , but at the cost of increased haematological toxicity . Developments in the clinical administration of gemcitabine are concentrating on efforts to extend the duration of exposure to the drug as a means of counteracting its rapid catabolism in the circulation. Future developments with this group of agents will further explore the use of fludarabine-based combination therapies to produce a transient period of myelosuppression and immunosuppression that is sufficient to permit the engraftment of allogeneic haemopoietic stem cells and also exploit the immunological benefits of graft-versus-tumour reactions. In addition, the clinical spectrum of activity of gemcitabine is also being extended by combining the drug with other active chemotherapeutic agents, such as cisplatin, and by early studies of its role as a radiosensitiser."}
{"sentence": "The pharmacodynamic effects of single doses of trazodone ( 100 mg ) , amitriptyline ( 50 mg ) or placebo either alone or with ethanol ( 0.5 ml/kg ) were investigated in 6 healthy volunteers in a double-blind crossover study .", "spans": [{"span_id": 0, "text": "trazodone", "start": 47, "end": 56, "token_start": 7, "token_end": 7}, {"span_id": 1, "text": "amitriptyline", "start": 70, "end": 83, "token_start": 13, "token_end": 13}, {"span_id": 2, "text": "ethanol", "start": 126, "end": 133, "token_start": 24, "token_end": 24}, {"span_id": 3, "text": "placebo", "start": 97, "end": 104, "token_start": 19, "token_end": 19}], "rels": [{"class": "COMB", "spans": [0, 2]}, {"class": "COMB", "spans": [1, 2]}, {"class": "COMB", "spans": [2, 3]}], "paragraph": "Evaluation of possible interactions between ethanol and trazodone or amitriptyline.  The pharmacodynamic effects of single doses of trazodone ( 100 mg ) , amitriptyline ( 50 mg ) or placebo either alone or with ethanol ( 0.5 ml/kg ) were investigated in 6 healthy volunteers in a double-blind crossover study . Plasma concentrations of the drugs and ethanol were also measured. Pharmacodynamic tests were critical flicker fusion frequency threshold (CFF), choice reaction time (CRT), manual dexterity, a digit span test and visual analogue scales. Blood ethanol concentrations were not influenced by the co-administration of either antidepressant. tmax for trazodone was prolonged by ethanol but the other pharmacokinetic parameters for trazodone and amitriptyline were not influenced by ethanol. trazodone and amitriptyline caused the expected profound depressant effects on CFF, CRT, manual dexterity and on the rating scales for drowsiness, 'clearheadedness', aggression and disinhibition. Ethanol alone impaired manual dexterity, increased drowsiness, reduced 'clearheadedness' and also tended to reduce feelings of aggression. In combination with either trazodone or amitriptyline, ethanol caused little additional effect except in the case of manual dexterity, which was further impaired. This result may reflect the profound effects of the antidepressants alone and does not suggest that it is safe for patients receiving antidepressant medication to take ethanolic drinks."}
{"sentence": "A 70-year-old Asian man was diagnosed with PVT two months after initiating 5-fluorouracil/leucovorin , irinotecan , and bevacizumab therapy for rectal cancer with liver metastases .", "spans": [{"span_id": 0, "text": "5-fluorouracil/leucovorin", "start": 75, "end": 100, "token_start": 12, "token_end": 12}, {"span_id": 1, "text": "irinotecan", "start": 103, "end": 113, "token_start": 14, "token_end": 14}, {"span_id": 2, "text": "bevacizumab", "start": 120, "end": 131, "token_start": 17, "token_end": 17}], "rels": [{"class": "COMB", "spans": [0, 1, 2]}], "paragraph": "Portal Vein Thrombosis in Metastatic Colorectal Cancer During FOLFIRI-bevacizumab Chemotherapy Successfully Treated with Apixaban. Portal vein thrombosis (PVT) while using an angiogenesis inhibitor is relatively rare. A 70-year-old Asian man was diagnosed with PVT two months after initiating 5-fluorouracil/leucovorin , irinotecan , and bevacizumab therapy for rectal cancer with liver metastases . Because the metastases were small and shrinking, we suspected that the thrombosis might have been caused by bevacizumab-containing chemotherapy. We stopped bevacizumab and started apixaban, a direct oral anticoagulant (DOAC). Eight months later, the complete dissolution of the thrombus and recanalization of the portal vein were attained. Our case suggests that PVT can occur during bevacizumab-containing chemotherapy, and DOAC therapy might be beneficial for treating PVT in patients with cancer."}
{"sentence": "All these isolates were found to survive in presence of heavy metals like cadmium , lead and zinc and were resistant to antibiotics like ampicillin , tetracycline , streptomycin , penicillin and chloramphenicol as indicated by their Minimum Inhibitory Concentrations ( MIC ) .", "spans": [{"span_id": 0, "text": "ampicillin", "start": 137, "end": 147, "token_start": 24, "token_end": 24}, {"span_id": 1, "text": "tetracycline", "start": 150, "end": 162, "token_start": 26, "token_end": 26}, {"span_id": 2, "text": "streptomycin", "start": 165, "end": 177, "token_start": 28, "token_end": 28}, {"span_id": 3, "text": "chloramphenicol", "start": 195, "end": 210, "token_start": 32, "token_end": 32}], "rels": [], "paragraph": "Identification and Characterization of the microbial communities found in electronic industrial effluent and their potential for bioremediation. Microbial communities are dynamic systems that develop depending on the ecological niche in which they survive. Electronic industry effluent, rich in heavy metals and salts is one such ecosystem where diverse heavy metal resistant microbes exist. Taxonomic identification of this microbial community would be interesting as no information on the microbial diversity from electronic industry effluent is available till date. Our paper attempts to characterize the microbial inhabitants of this niche. Culture dependent microbiological methods were used to establish and identify various microbial species from the effluent. Culture independent methods of identification involving biochemical tests and molecular biology based methods like 16 S- r DNA sequencing and lipid analyses (FAME analysis) were also carried out to confirm the identity of isolated species. Our study, first of its kind revealed the presence of a diverse group of resistant aerobic microbes and disclosed a total of ten bacterial and two fungal isolates. All these isolates were found to survive in presence of heavy metals like cadmium , lead and zinc and were resistant to antibiotics like ampicillin , tetracycline , streptomycin , penicillin and chloramphenicol as indicated by their Minimum Inhibitory Concentrations ( MIC ) . Such resistant isolates harbor possibilities of metal adaptive/selective pathways which render them as economically beneficial bio-sorbent alternatives in bioremediation of heavy metals."}
{"sentence": "Results of cell viability assays revealed that treatment with a combination of imatinib and chemotherapy agents irinotecan or 5\u2011Fu synergistically inhibited cell growth , compared with treatment with any of these drugs alone .", "spans": [{"span_id": 0, "text": "imatinib", "start": 79, "end": 87, "token_start": 12, "token_end": 12}, {"span_id": 1, "text": "irinotecan", "start": 112, "end": 122, "token_start": 16, "token_end": 16}, {"span_id": 2, "text": "5\u2011Fu", "start": 126, "end": 130, "token_start": 18, "token_end": 18}], "rels": [{"class": "POS", "spans": [0, 1]}, {"class": "POS", "spans": [0, 2]}], "paragraph": "Imatinib\u2011induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress. imatinib is a powerful tyrosine kinase inhibitor that specifically targets BCR\u2011ABL, c\u2011KIT, and PDGFR kinases, and is used in the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors, and other types of cancers. However, the possible anticancer effects of imatinib in gastric cancer have not yet been explored. The present study evaluated the in\u00a0vitro effects of imatinib on gastric cancer cells and determined the molecular mechanism underlying these effects. We determined that imatinib induced mitochondria\u2011mediated apoptosis of gastric cancer cells by involving endoplasmic reticulum (ER) stress\u2011associated activation of c\u2011Jun NH2\u2011terminal kinase (JNK). We also found that imatinib suppressed cell proliferation in a time\u2011\u00a0and dose\u2011dependent manner. Cell cycle analysis revealed that imatinib\u2011treated AGS cells were arrested in the G2/M\u00a0phase of the cell cycle. Moreover, imatinib\u2011treated cells exhibited increased levels of phosphorylated JNK, and of the transcription factor\u00a0C/EBP homologous protein, an ER stress\u2011associated apoptotic molecule. Results of cell viability assays revealed that treatment with a combination of imatinib and chemotherapy agents irinotecan or 5\u2011Fu synergistically inhibited cell growth , compared with treatment with any of these drugs alone . These data indicated that imatinib exerted cytotoxic effects on gastric cancer cells by inducing apoptosis mediated by reactive oxygen species generation and ER stress\u2011associated JNK activation. Furthermore, we revealed that imatinib induced the apoptosis of gastric cancer cells by inhibiting platelet\u2011derived growth factor receptor signaling. Collectively, our results strongly support the use of imatinib in the treatment of treating gastric cancer."}
{"sentence": "We concluded that ifosfamide is an active agent even in patients with tumours resistant to cyclophosphamide .", "spans": [{"span_id": 0, "text": "ifosfamide", "start": 18, "end": 28, "token_start": 3, "token_end": 3}, {"span_id": 1, "text": "cyclophosphamide", "start": 91, "end": 107, "token_start": 15, "token_end": 15}], "rels": [], "paragraph": "Ifosfamide in the treatment of high-grade recurrent non-Hodgkin's lymphomas. We report the results of two phase II trials of ifosfamide in very high risk patients with either partially responsive or recurrent non-Hodgkin's lymphomas. In the first study, in which patients were extremely heavily pretreated (50 per cent had received a very intensive salvage regimen containing very high dose cyclophosphamide), there were two complete responses, two partial responses and one objective (minimal) response among 14 patients treated. Toxicity was acceptable even in this end-stage patient group. We concluded that ifosfamide is an active agent even in patients with tumours resistant to cyclophosphamide . The second trial was a pilot study in 13 patients of a regimen incorporating VP16, ifosfamide/mesna, and high dose ara-C (VIPA). There were four complete responses, five partial responses and two objective responses. Two patients died in complete remission from toxic complications, while a third, with a stably regressed mediastinal mass died after completion of the protocol. While very toxic, we considered that this regimen was highly effective, and have since incorporated a slightly less intensive combination of the same drugs into the primary therapy of high risk patients. Since the primary toxicity of the VIPA combination was myelosuppression, the use of a modified protocol incorporating colony stimulating factors to ameliorate the side-effects and possibly increase dose rate is worthy of further exploration in patients with recurrent B cell tumours."}
{"sentence": "Reduction of ASS1 expression by siRNA significantly sensitized mesothelioma spheroids to the pro-apoptotic effects of bortezomib and of cisplatin plus pemetrexed .", "spans": [{"span_id": 0, "text": "bortezomib", "start": 118, "end": 128, "token_start": 15, "token_end": 15}, {"span_id": 1, "text": "pemetrexed", "start": 151, "end": 161, "token_start": 20, "token_end": 20}, {"span_id": 2, "text": "cisplatin", "start": 136, "end": 145, "token_start": 18, "token_end": 18}], "rels": [{"class": "POS", "spans": [1, 2]}], "paragraph": "Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma. To investigate the underlying causes of chemoresistance in malignant pleural mesothelioma, we have studied mesothelioma cell lines as 3D spheroids, which acquire increased chemoresistance compared to 2D monolayers. We asked whether the gene expression of 3D spheroids would reveal mechanisms of resistance. To address this, we measured gene expression of three mesothelioma cell lines, M28, REN and VAMT, grown as 2D monolayers and 3D spheroids. A total of 209 genes were differentially expressed in common by the three cell lines in 3D (138 upregulated and 71 downregulated), although a clear resistance pathway was not apparent. We then compared the list of 3D genes with two publicly available datasets of gene expression of 56 pleural mesotheliomas compared to normal tissues. Interestingly, only three genes were increased in both 3D spheroids and human tumors: argininosuccinate synthase 1 (ASS1), annexin A4 (ANXA4) and major vault protein (MVP); of these, ASS1 was the only consistently upregulated of the three genes by qRT-PCR. To measure ASS1 protein expression, we stained 2 sets of tissue microarrays (TMA): one with 88 pleural mesothelioma samples and the other with additional 88 pleural mesotheliomas paired with matched normal tissues. Of the 176 tumors represented on the two TMAs, ASS1 was expressed in 87 (50%; staining greater than 1 up to 3+). For the paired samples, ASS1 expression in mesothelioma was significantly greater than in the normal tissues. Reduction of ASS1 expression by siRNA significantly sensitized mesothelioma spheroids to the pro-apoptotic effects of bortezomib and of cisplatin plus pemetrexed . Although mesothelioma is considered by many to be an ASS1-deficient tumor, our results show that ASS1 is elevated at the mRNA and protein levels in mesothelioma 3D spheroids and in human pleural mesotheliomas. We also have uncovered a survival role for ASS1, which may be amenable to targeting to undermine mesothelioma multicellular resistance. "}
{"sentence": "The combination of a fluoropyrimidine ( 5-fluorouracil or capecitabine ) with either oxaliplatin or irinotecan has been widely accepted as standard cytotoxic chemotherapy for either the first- or second-line treatment of mCRC .", "spans": [{"span_id": 0, "text": "fluoropyrimidine", "start": 21, "end": 37, "token_start": 4, "token_end": 4}, {"span_id": 1, "text": "5-fluorouracil", "start": 40, "end": 54, "token_start": 6, "token_end": 6}, {"span_id": 2, "text": "capecitabine", "start": 58, "end": 70, "token_start": 8, "token_end": 8}, {"span_id": 3, "text": "oxaliplatin", "start": 85, "end": 96, "token_start": 12, "token_end": 12}, {"span_id": 4, "text": "irinotecan", "start": 100, "end": 110, "token_start": 14, "token_end": 14}], "rels": [{"class": "COMB", "spans": [2, 3]}, {"class": "COMB", "spans": [0, 4]}, {"class": "COMB", "spans": [2, 4]}], "paragraph": "Options for Second-Line Treatment in Metastatic Colorectal Cancer. Colorectal cancer (CRC) remains a major public health problem in the United States and worldwide. The majority of patients who have CRC eventually present with metastatic disease. The overall therapeutic goals for most patients with metastatic CRC (mCRC) are to control the disease, prolong life span, and maximize quality of life. Therefore, the ratio of efficacy to toxicity is one of the most important factors in choosing among treatment options and sequencing regimens. In addition, the choice of first-line systemic therapy will affect the options for second-line treatment. Several newer cytotoxic agents for the treatment of mCRC have been approved during the past 2 decades by the US Food and Drug Administration (FDA), including irinotecan, oxaliplatin, and capecitabine. The combination of a fluoropyrimidine ( 5-fluorouracil or capecitabine ) with either oxaliplatin or irinotecan has been widely accepted as standard cytotoxic chemotherapy for either the first- or second-line treatment of mCRC . The FDA has approved several pathway-targeting agents for the treatment of mCRC; these include agents that target the vascular endothelial growth factor receptor pathway (bevacizumab, ziv-aflibercept, and ramucirumab) and those that target the epidermal growth factor receptor pathway (cetuximab and panitumumab). Here, we review the current clinical options for the second-line treatment of mCRC and the rationales for their use. "}
{"sentence": "In 1517 poor prognosis patients , 21 regimens were used , the commonest being CAV , EV ( etoposide , vincristine ) , CbE , CAV alternating with PE , and oral etoposide .", "spans": [{"span_id": 0, "text": "etoposide", "start": 89, "end": 98, "token_start": 18, "token_end": 18}, {"span_id": 1, "text": "vincristine", "start": 101, "end": 112, "token_start": 20, "token_end": 20}, {"span_id": 2, "text": "etoposide", "start": 158, "end": 167, "token_start": 32, "token_end": 32}], "rels": [], "paragraph": "A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom. Many chemotherapy regimens are used for treating SCLC in the United Kingdom, but it is not known, in any detail, which regimens are used, by which specialists, for which types of patient. We conducted a survey among all medical and clinical oncologists, respiratory physicians and general physicians with respiratory interest in the United Kingdom to find out. The questionnaire asked for the number of SCLC patients treated annually; how many were given chemotherapy; the drugs, doses and schedules chosen according to prognostic group (as defined by the clinician); and the reasons for choice of regimen. 1214 questionnaires were sent out, and responses were received from 1070 (88%) clinicians; 266 (25%) of these treated SCLC with chemotherapy. Of 4674 patients given chemotherapy annually, 36% were given it by clinical oncologists, 30% by medical oncologists, 27% by respiratory physicians, and 7% by general physicians. In all, 34 regimens were reported with 151 different combinations of dose and schedule. In 2311 good prognosis patients, 23 regimens were used, the commonest being ACE (doxorubicin, cyclophosphamide, etoposide), ICbE (ifosfamide, carboplatin, etoposide), CAV (cyclophosphamide, doxorubicin, vincristine), CbE (carboplatin, etoposide), and PE (cisplatin, etoposide). In 1517 poor prognosis patients , 21 regimens were used , the commonest being CAV , EV ( etoposide , vincristine ) , CbE , CAV alternating with PE , and oral etoposide . 452 patients were treated regardless of prognosis and for 219 no prognostic criteria were specified. The remaining 175 were given second-line chemotherapy or were given regimens chosen to avoid toxicity or because of intercurrent disease or other reasons. The main reasons affecting choice of regimen were routine local practice, patients' convenience, quality of life considerations, trial results and cost. The results show wide variation in routine practice and will be useful in reporting and planning clinical trials and in deciding on local treatment policies."}
{"sentence": "Utilizing this data , we suggest that nivolumab plus ipilimumab and cabozantinib may be favored for first-line treatment of specific populations of older patients .", "spans": [{"span_id": 0, "text": "nivolumab", "start": 38, "end": 47, "token_start": 7, "token_end": 7}, {"span_id": 1, "text": "ipilimumab", "start": 53, "end": 63, "token_start": 9, "token_end": 9}, {"span_id": 2, "text": "cabozantinib", "start": 68, "end": 80, "token_start": 11, "token_end": 11}], "rels": [{"class": "POS", "spans": [0, 1, 2]}], "paragraph": "Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. Given the underrepresentation of older patients in registration trials for metastatic renal cell carcinoma (mRCC), data to support the use of any particular systemic therapy over others, based on age, is limited. This is further complicated by clinical trials not commonly reporting adverse events by age. Thus, recommendations on treatment of older patients with mRCC are generally extrapolated from data on younger patients enrolled in these trials, which may not be ideal as many older patients are frail, have age-related organ dysfunction, or have multiple medical co-morbidities. In the last decade, the treatment landscape for mRCC has drastically changed with the approval of more than ten targeted therapies, as well as immune checkpoint inhibitors. Thus, treatment selection and sequencing of treatments can be especially challenging for clinicians. We begin this review by analyzing the available efficacy and toxicity data of these treatments in younger and older patients. We also discuss a network meta-analysis that compares the efficacy of these agents in older patients with mRCC. Utilizing this data , we suggest that nivolumab plus ipilimumab and cabozantinib may be favored for first-line treatment of specific populations of older patients . For salvage treatment, we suggest that cabozantinib may be the preferred agent for older patients."}
{"sentence": "In conclusion , the combination of thalidomide and cyclosporine in subtherapeutic doses may be useful for the treatment of skin allografts .", "spans": [{"span_id": 0, "text": "thalidomide", "start": 35, "end": 46, "token_start": 6, "token_end": 6}, {"span_id": 1, "text": "cyclosporine", "start": 51, "end": 63, "token_start": 8, "token_end": 8}], "rels": [{"class": "POS", "spans": [0, 1]}], "paragraph": "Effects of thalidomide, cyclosporine, and diclofenac on skin allograft survival in rabbits. The present study evaluated the effects of thalidomide, cyclosporine, and diclofenac on skin allograft survival in 42 rabbits divided into the following groups (n = 6): group 1, autograft control; group 2, allograft control; group 3, allografts under thalidomide (100 mg/kg/d); group 4, allografts under sodium diclofenac (2 mg/kg/d); group 5, allografts under cyclosporine (10 mg/kg/d); group 6, allografts under cyclosporine (5 mg/kg/d); group 7, allografts under cyclosporine (5 mg/kg/d) plus thalidomide (100 mg/kg/d). The drugs were given via the orogastric tube the day before transplantation and daily during the postoperative period. Total circular skin grafts from the ear were exchanged between California and White New Zealand rabbits. cyclosporine (10 mg/kg/d) increased allograft survival, an effect that was comparable to cyclosporine (5 mg/kg/d) plus thalidomide (100 mg/kg/d). thalidomide and diclofenac given alone had minimally significant effects on the mean survival of skin allografts. The number of eosinophils around the necrotic skin was higher in the diclofenac group. The group receiving cyclosporine combined with thalidomide displayed the lowest number of eosinophils surrounding the allograft. In conclusion , the combination of thalidomide and cyclosporine in subtherapeutic doses may be useful for the treatment of skin allografts ."}
{"sentence": "We now wish to report that , under these conditions , the pss-8 mutant is hypersensitive to certain antibiotics , especially to streptomycin , kanamycin , and gentamicin , although also to ampicillin and novobiocin .", "spans": [{"span_id": 0, "text": "streptomycin", "start": 128, "end": 140, "token_start": 22, "token_end": 22}, {"span_id": 1, "text": "kanamycin", "start": 143, "end": 152, "token_start": 24, "token_end": 24}, {"span_id": 2, "text": "gentamicin", "start": 159, "end": 169, "token_start": 27, "token_end": 27}, {"span_id": 3, "text": "ampicillin", "start": 189, "end": 199, "token_start": 32, "token_end": 32}, {"span_id": 4, "text": "novobiocin", "start": 204, "end": 214, "token_start": 34, "token_end": 34}], "rels": [], "paragraph": "Envelope composition and antibiotic hypersensitivity of Escherichia coli mutants defective in phosphatidylserine synthetase. Mutants of Escherichia coli K12, defective in phosphatidylserine synthetase (pss), can be isolated as temperature-sensitive, conditional lethals. When cultivated at intermediate temperatures (30 degrees), such mutants contain approximately 3 times more phosphatidylglycerol plus cardiolipin (and less phosphatidylethanolamine) than normal. We now wish to report that , under these conditions , the pss-8 mutant is hypersensitive to certain antibiotics , especially to streptomycin , kanamycin , and gentamicin , although also to ampicillin and novobiocin . At 30 degrees, the membrane protein and fatty acid composition of pss-8 is nearly normal, i.e. identical with an isogenic pss+ organism. Radiochemical labeling and bacteriophage growth studies show that lipopolysaccharide is also unaltered. Therefore, the antibiotic hypersensitivity of pss-8 differs from previously reported hypersensitivities, associated with lipopolysaccharide defects. These results suggest that the polar phospholipid headgroups may play an important role in maintaining the barrier function of the outer gramnegative membrane and that putative inhibitors of the phosphatidylserine synthetase might potentiate the action of numerous antibiotics currently in clinical use."}
{"sentence": "During the first 5 min of cooling , CVC decreased at control sites ( lactated Ringer solution ) to -45 + /- 6 % ( P < 0.001 ) , increased at adrenoceptor-antagonized sites ( yohimbine + propranolol ) to 15 + /- 14 % ( P = 0.002 ) , and remained unchanged at both Rho kinase-inhibited ( fasudil ) and adrenoceptor-antagonized + Rho kinase-inhibited sites ( yohimbine + propranolol + fasudil ) ( -9 + /- 1 % , P = 0.4 and -6 + /- 2 % , P = 0.4 , respectively ) .", "spans": [{"span_id": 0, "text": "yohimbine", "start": 174, "end": 183, "token_start": 35, "token_end": 35}, {"span_id": 1, "text": "propranolol", "start": 186, "end": 197, "token_start": 37, "token_end": 37}, {"span_id": 2, "text": "fasudil", "start": 286, "end": 293, "token_start": 59, "token_end": 59}, {"span_id": 3, "text": "yohimbine", "start": 356, "end": 365, "token_start": 68, "token_end": 68}, {"span_id": 4, "text": "propranolol", "start": 368, "end": 379, "token_start": 70, "token_end": 70}, {"span_id": 5, "text": "fasudil", "start": 382, "end": 389, "token_start": 72, "token_end": 72}], "rels": [], "paragraph": "Cold-induced cutaneous vasoconstriction is mediated by Rho kinase in vivo in human skin. Cutaneous vasoconstriction (VC) is the initial thermoregulatory response to cold exposure and can be elicited through either whole body or localized skin cooling. However, the mechanisms governing local cold-induced VC are not well understood. We tested the hypothesis that Rho kinase participates in local cold-induced cutaneous VC. In seven men and women (20-27 yr of age), up to four ventral forearm skin sites were instrumented with intradermal microdialysis fibers for localized drug delivery during cooling. Skin blood flow was monitored at each site with laser-Doppler flowmetry while local skin temperature was decreased and maintained at 24 degrees C for 40 min. Cutaneous vascular conductance (CVC; laser-Doppler flowmetry/mean arterial pressure) was expressed as percent change from 34 degrees C baseline. During the first 5 min of cooling , CVC decreased at control sites ( lactated Ringer solution ) to -45 + /- 6 % ( P < 0.001 ) , increased at adrenoceptor-antagonized sites ( yohimbine + propranolol ) to 15 + /- 14 % ( P = 0.002 ) , and remained unchanged at both Rho kinase-inhibited ( fasudil ) and adrenoceptor-antagonized + Rho kinase-inhibited sites ( yohimbine + propranolol + fasudil ) ( -9 + /- 1 % , P = 0.4 and -6 + /- 2 % , P = 0.4 , respectively ) . During the last 5 min of cooling, CVC further decreased at all sites when compared with baseline values (control, -77 +/- 4%, P < 0.001; adrenoceptor antagonized, -61 +/- 3%, P < 0.001; Rho kinase inhibited, -34 +/- 7%, P < 0.001; and adrenoceptor antagonized + Rho kinase inhibited sites, -35 +/- 3%, P < 0.001). Rho kinase-inhibited and combined treatment sites were significantly attenuated when compared with both adrenoceptor-antagonized (P < 0.01) and control sites (P < 0.0001). Rho kinase mediates both early- and late-phase cold-induced VC, supporting in vitro findings and providing a putative mechanism through which both adrenergic and nonadrenergic cold-induced VC occurs in an in vivo human thermoregulatory model."}
{"sentence": "The aim of this study was to evaluate all E. coli positive blood cultures collected during a 4-y period in a haematological department using piperacillin plus netilmicin for empiric treatment of febrile episodes .", "spans": [{"span_id": 0, "text": "piperacillin", "start": 141, "end": 153, "token_start": 24, "token_end": 24}, {"span_id": 1, "text": "netilmicin", "start": 159, "end": 169, "token_start": 26, "token_end": 26}], "rels": [{"class": "COMB", "spans": [0, 1]}], "paragraph": "Piperacillin-resistant Escherichia coli bacteraemia: relation to empiric therapy and clinical outcome. Escherichia coli is a leading cause of bacteraemia. The aim of this study was to evaluate all E. coli positive blood cultures collected during a 4-y period in a haematological department using piperacillin plus netilmicin for empiric treatment of febrile episodes . We measured the incidence of piperacillin-resistant E. coli bacteraemia among haematological and non-haematological patients, described the importance of previous antibiotic treatment for resistance development in E. coli and evaluated the impact of piperacillin resistance on the clinical outcome of E. coli bacteraemia. 114 episodes of E. coli bacteraemia in 104 patients were recorded and 98 episodes in 88 patients (42 males and 46 females) with a median age of 64 y (range 19-85 y) were evaluated. In 81.6% of the episodes the patients had a haematological disorder, dominated by acute leukaemia (41.3%), chronic leukaemia (16.3%) and lymphoma (10%). The proportion of piperacillin-resistant E. coli was higher among haematological patients than non-haematological patients (25% vs 0%, p=0.02) and resistance was associated with piperacillin therapy during the previous month (p=0.05). No difference in clinical outcome was found between haematological patients infected with piperacillin-susceptible or -resistant E. coli (intensive care 12% vs 15%; mortality 22% vs 25%)."}
{"sentence": "Thirty-five percent ( 6 of 17 ) of the patients receiving docetaxel alone and 53 % ( 19 of 36 ) of those receiving docetaxel and thalidomide have had a PSA decrease of at least 50 % .", "spans": [{"span_id": 0, "text": "docetaxel", "start": 58, "end": 67, "token_start": 11, "token_end": 11}, {"span_id": 1, "text": "docetaxel", "start": 115, "end": 124, "token_start": 24, "token_end": 24}, {"span_id": 2, "text": "thalidomide", "start": 129, "end": 140, "token_start": 26, "token_end": 26}], "rels": [{"class": "POS", "spans": [1, 2]}], "paragraph": "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. New therapeutic alternatives are needed to improve outcomes in patients with androgen-independent prostate cancer (AIPC). For several years, researchers at the National Cancer Institute have been interested in elucidating the importance of angiogenesis in the pathogenesis of prostate cancer and in identifying inhibitors of this process. thalidomide has been shown to inhibit the ability of tumors to recruit new blood vessels. In a recent phase II trial of thalidomide in AIPC, 28% of patients achieved a prostate-specific antigen (PSA) decrease of >40%. The taxane docetaxel also produces PSA and measurable disease responses when used as monotherapy or as a component of combination chemotherapy for AIPC. Thus, based on the single-agent activity of thalidomide and docetaxel, we initiated a randomized phase II study of weekly docetaxel with or without thalidomide, 200 mg at bedtime, in patients with chemotherapy-naive metastatic AIPC. docetaxel, 30 mg/m(2) intravenously, was administered every 7 days for 3 weeks, followed by a 1-week rest period. Both regimens have been well tolerated among the first 59 treated patients, with a near absence of grade (3/4) myelosuppression. Fatigue, hyperglycemia, and pulmonary toxicity were seen in both groups. Thrombotic events have been seen in the combination arm. Thirty-five percent ( 6 of 17 ) of the patients receiving docetaxel alone and 53 % ( 19 of 36 ) of those receiving docetaxel and thalidomide have had a PSA decrease of at least 50 % . Combining a cytotoxic agent with an angiogenesis inhibitor is a promising area of investigation for prostate cancer management."}
{"sentence": "Evidence-based guidelines recommend nicotine replacement therapy , bupropion SR , and varenicline as effective alternatives for smoking cessation therapy , especially when combined with behavioral interventions .", "spans": [{"span_id": 0, "text": "nicotine", "start": 36, "end": 44, "token_start": 3, "token_end": 3}, {"span_id": 1, "text": "bupropion", "start": 67, "end": 76, "token_start": 7, "token_end": 7}, {"span_id": 2, "text": "varenicline", "start": 86, "end": 97, "token_start": 11, "token_end": 11}], "rels": [], "paragraph": "Smoking cessation intervention: an evidence-based approach. Cigarette smoking represents the most important source of preventable morbidity and premature mortality worldwide. Approximately 100 million deaths were caused by tobacco use in the 20th century. There are >1 billion smokers worldwide, and globally the use of tobacco products is increasing, with the epidemic shifting to the developing world. Tobacco dependence is a chronic condition that often requires repeated intervention for success. Just informing a patient about health risks, although necessary, is usually not sufficient for a decision to change. Smokers should be provided with counseling when attempting to quit. Pharmacologic smoking cessation aids are recommended for all smokers who are trying to quit, unless contraindicated. Evidence-based guidelines recommend nicotine replacement therapy , bupropion SR , and varenicline as effective alternatives for smoking cessation therapy , especially when combined with behavioral interventions . Combination pharmacotherapy is indicated for highly nicotine-dependent smokers, patients who have failed with monotherapy, and patients with breakthrough cravings. An additional form of nicotine replacement therapy or an addition of a non-nicotine replacement therapy oral medication (bupropion or varenicline) may be helpful. The rate of successful smoking cessation at 1 year is 3% to 5% when the patient simply tries to stop, 7% to 16% if the smoker undergoes behavioral intervention, and up to 24% when receiving pharmacological treatment and behavioral support."}
{"sentence": "The efficacy of methotrexate ( MTX ) as a single graft-versus-host disease ( GVHD ) prophylaxis agent was compared to that of cyclosporin A ( CSA ) in 62 pediatric patients ( median age : 8 years ) with hematological malignancies who had undergone bone marrow transplantation ( BMT ) from HLA-identical sibling donors at National Kyushu Cancer Center since 1977 .", "spans": [{"span_id": 0, "text": "methotrexate", "start": 16, "end": 28, "token_start": 3, "token_end": 3}, {"span_id": 1, "text": "cyclosporin", "start": 126, "end": 137, "token_start": 22, "token_end": 22}], "rels": [], "paragraph": "Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.  The efficacy of methotrexate ( MTX ) as a single graft-versus-host disease ( GVHD ) prophylaxis agent was compared to that of cyclosporin A ( CSA ) in 62 pediatric patients ( median age : 8 years ) with hematological malignancies who had undergone bone marrow transplantation ( BMT ) from HLA-identical sibling donors at National Kyushu Cancer Center since 1977 . In all, 30 patients received MTX by intravenous bolus injection, with a dose of 15 mg/m(2) on day +1, followed by 10 mg/m(2) on days +3, +6, and +11, and then once a week until day +100. A total of 32 patients were treated with CSA, which was given intravenously in the early stages and orally thereafter until day +100, and then gradually tapered and stopped 6 months after BMT. There were no differences between the groups in terms of rates of hematopoietic recovery after BMT. The probabilities of acute GVHD (grades II-IV) and chronic GVHD were 29.6 vs 40.6% (P=0.294) and 19 vs 20% (MTX vs CSA), respectively. Relapse rates and event-free survival were identical. These results suggest that MTX and CSA were equally effective when given after BMT in Japanese pediatric patients with hematological malignancies. Since MTX was given over a shorter time than CSA, it might be more practical in the management of such patients."}
{"sentence": "Owing to the wide spread activation of this pathway in numerous neoplasms , trametinib and cobimetinib are being studied in combination with other targeted and cytotoxic drugs in a variety of clinical situations .", "spans": [{"span_id": 0, "text": "trametinib", "start": 76, "end": 86, "token_start": 13, "token_end": 13}, {"span_id": 1, "text": "cobimetinib", "start": 91, "end": 102, "token_start": 15, "token_end": 15}], "rels": [], "paragraph": "Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. The Ras-Raf-MEK-ERK (Map kinase) cellular pathway is a highly conserved eukaryotic signaling module that transduces extracellular signals from growth factors and cytokines into intracellular regulatory events that are involved in cell growth and proliferation or the contrary pathway of cell differentiation. Dysregulation of this pathway occurs in more than one-third of all malignancies, a process that has fostered the development of targeted Map kinase pathway inhibitors. Cutaneous melanomas, which arise from skin melanocytes, are the most aggressive form of skin cancer. Mutations that activate the Map kinase pathway occur in more than 90% of these melanomas. This has led to the development of the combination of dabrafenib and trametinib or vemurafenib and cobimetanib for the treatment of BRAF V600E mutant melanomas. dabrafenib and vemurafenib target V600E/K BRAF mutants while trametinib and cobimetanib target MEK1/2. The latter two agents bind to MEK1/2 at a site that is adjacent to, but separate from, the ATP-binding site and are therefore classified as type III allosteric protein kinase inhibitors. These agents form a hydrogen bond with a conserved \u03b23-lysine and they make numerous hydrophobic contacts with residues within the \u03b1C-helix, the \u03b25 strand, and within the activation segment, regions of the protein kinase domain that exhibit greater diversity than those found within the ATP-binding site. One advantage of such allosteric inhibitors is that they do not have to compete with millimolar concentrations of cellular ATP, which most FDA-approved small molecule competitive inhibitors such as imatinib must do. Owing to the wide spread activation of this pathway in numerous neoplasms , trametinib and cobimetinib are being studied in combination with other targeted and cytotoxic drugs in a variety of clinical situations . Except for BRAF and NRAS mutations, there are no other biomarkers correlated with treatment responses following MEK1/2 inhibition and the discovery of such biomarkers would represent an important therapeutic breakthrough."}
{"sentence": "Rats were subchronically primed with nicotine , clozapine or saline .", "spans": [{"span_id": 0, "text": "nicotine", "start": 37, "end": 45, "token_start": 5, "token_end": 5}, {"span_id": 1, "text": "clozapine", "start": 48, "end": 57, "token_start": 7, "token_end": 7}, {"span_id": 2, "text": "saline", "start": 61, "end": 67, "token_start": 9, "token_end": 9}], "rels": [{"class": "COMB", "spans": [0, 1, 2]}], "paragraph": "Nicotine and clozapine cross-prime the locus coeruleus noradrenergic system to induce long-lasting potentiation in the rat hippocampus. A priming-challenge schedule of nicotine treatment causes long-lasting potentiation (LLP), a form of synaptic plasticity closely associated with the norepinephrine (NE) neurotransmitter system, at the medial perforant path (MPP)-dentate gyrus (DG) synapse in the rat hippocampus. Previous reports revealed that nicotine activates the locus coeruleus (LC) noradrenergic (NAergic) system and this mechanism may underlie its beta-adrenoceptor sensitive LLP effects. clozapine, an atypical antipsychotic, is also known to activate the LC. Interactions between nicotine and clozapine are of interest because of the prevalence of smoking in patients with schizophrenia and increasing interest in the use of nicotinic receptor ligands as cognitive enhancers. Rats were subchronically primed with nicotine , clozapine or saline . Twenty-one to twenty-eight days later, the effects of the nicotine, clozapine or saline challenge on the evoked field excitatory postsynaptic potentials (fEPSP) at the MPP-DG monosynaptic pathway were recorded as a measure of LLP. We confirmed the hypothesis that a challenge dose of either nicotine or clozapine induces LLP exclusively in nicotine- and clozapine-primed rats, and not in saline-primed rats, thus indicating a cross-priming effect. Moreover, unilateral suppression of LC using lidocaine abolished the LLP induced by nicotine in clozapine-primed rats. Furthermore, systemic treatment with clonidine (an \u03b12 adrenoceptor agonist that reduces NAergic activity via autoreceptors) prior to the challenge doses blocked the nicotine/clozapine-induced LLP in nicotine- and clozapine-primed rats. These findings may add to understanding of the cognitive enhancing effects of nicotine."}
{"sentence": "The chimeric anti- EGFR monoclonal antibody cetuximab has been approved for EGFR-expressing colorectal tumors in patients who progress after irinotecan-based chemotherapy in combination with irinotecan and in squamous cell head and neck carcinomas for patients with locally advanced disease in combination with radiation therapy or after failure of platinum-based chemotherapy in recurrent or metastatic disease ( FDA ) .", "spans": [{"span_id": 0, "text": "cetuximab", "start": 44, "end": 53, "token_start": 6, "token_end": 6}, {"span_id": 1, "text": "irinotecan", "start": 191, "end": 201, "token_start": 24, "token_end": 24}], "rels": [], "paragraph": "The future of anti-EGFR therapy. We report here on the state of our knowledge of the target--namely, the epidermal growth factor (EGF) and its receptor--and the challenges related to the methods of determination of the epidermal growth factor receptor (EGFR) and associated molecular pathways. A critical review of the anti-EGFR therapeutic strategies is also outlined. The chimeric anti- EGFR monoclonal antibody cetuximab has been approved for EGFR-expressing colorectal tumors in patients who progress after irinotecan-based chemotherapy in combination with irinotecan and in squamous cell head and neck carcinomas for patients with locally advanced disease in combination with radiation therapy or after failure of platinum-based chemotherapy in recurrent or metastatic disease ( FDA ) . cetuximab has the potential to provide an improvement of clinical outcome also in other indications and tumor types, particularly when used as first-line therapy combined with standard chemotherapy for metastatic disease or in the adjuvant setting. Possible strategies to improve the effectiveness of anti-EGFR agents are suggested and include (i) the use of predictive tools capable of making a more rational selection of patients; (ii) the development of standardized predictive biomarkers as surrogates for early monitoring of drug efficacy; and (iii) adequate study design, statistical analysis and proper end points of efficacy to be applied in future prospective trials."}
{"sentence": "New agents , such as taxane , irinotecan and oxaliplatin , combined with old agents , such as cisplatin and 5-FU , are currently under evaluation to further improve treatment outcomes .", "spans": [{"span_id": 0, "text": "irinotecan", "start": 30, "end": 40, "token_start": 7, "token_end": 7}, {"span_id": 1, "text": "oxaliplatin", "start": 45, "end": 56, "token_start": 9, "token_end": 9}, {"span_id": 2, "text": "taxane", "start": 21, "end": 27, "token_start": 5, "token_end": 5}, {"span_id": 3, "text": "cisplatin", "start": 94, "end": 103, "token_start": 18, "token_end": 18}, {"span_id": 4, "text": "5-FU", "start": 108, "end": 112, "token_start": 20, "token_end": 20}], "rels": [{"class": "COMB", "spans": [2, 3, 4]}, {"class": "COMB", "spans": [0, 3, 4]}, {"class": "COMB", "spans": [1, 3, 4]}], "paragraph": "Chemotherapy for advanced gastric cancer: slow but further progress. Gastric cancer remains a significant problem in terms of global health, and is the most common cancer in Korea. Surgery is the only potentially curative treatment for localized gastric cancer, but most cases present at an advanced stage. Randomized trials have demonstrated that chemotherapy for advanced gastric cancer improves the quality of life and extends survival, by 4 approximately 6 months, compared with best supportive care alone. Single agents with a proven activity in a first-line setting include 5-fluorouracil (5-FU), doxorubicin, mitomycin C, cisplatin, taxanes (docetaxel and paclitaxel) and oral fluoropyrimidines (capecitabine and TS-1). Based on the results from several large scale randomized trials, FP (5-FU/cisplatin) and ECF (epirubicin/cisplatin/5-FU) combinations are the most widely used regimen against advanced gastric cancer. Phase II studies of the FP and ECF combination reported a 40~51% response rate in previously untreated patients, and this regimen also produced a significantly higher response rate than the FAM (5-FU/doxorubicin/mitomycin) and FAMTX (5-FU/doxorubicin/methotrexate) regimens, respectively. However, significant treatment related-toxicities and discomfort were reported from ECF, which prevents this combination from becoming the standard treatment regimen. While no one combination chemotherapy regimen is accepted as the standard for advanced gastric cancer, FP is currently considered a suitable reference regimen worldwide. New agents , such as taxane , irinotecan and oxaliplatin , combined with old agents , such as cisplatin and 5-FU , are currently under evaluation to further improve treatment outcomes . Also, oral 5-FU prodrugs are replacing the cumbersome 5-FU long-term infusion due to its convenience and superior toxicity profile. However, the low complete response rate and short response duration are still the main obstacles in the chemotherapy for gastric cancer. Only large scale comparative clinical trials will give clues to improve the results of gastric cancer treatments."}
{"sentence": "Taxinol , Gemcitabine ( GEM ) , Navelbine ( NVB ) , Edatrexate ( ETX ) , CPT-11 and high dose Epirubicin ( EPI HD ) are recommended as new effective drugs .", "spans": [{"span_id": 0, "text": "Gemcitabine", "start": 10, "end": 21, "token_start": 2, "token_end": 2}, {"span_id": 1, "text": "Epirubicin", "start": 94, "end": 104, "token_start": 21, "token_end": 21}], "rels": [], "paragraph": "Non-surgical therapy for patients with advanced non-small cell lung cancer. Advanced non-small cell lung cancer (NSCLC) denotes those of TNM stage III and IV. NSCLC has its specific characteristics in respect of oncological behaviour, molecular biology, sensitivity to chemotherapy (CT) and radiotherapy (RT), and requires different therapeutic strategies in comparison with small cell lung cancer. The therapies include: (1) surgery in combination with new effective drugs is resulted in improved RR from 15% a decade ago to 40-60% today. Cisplatin (C-DDP) is the most attractive drug in the treatment of NSCLC, in lengthening the life-span of Stage IV NSCLC patients and as an indispensable sensitizer in RT. Taxinol , Gemcitabine ( GEM ) , Navelbine ( NVB ) , Edatrexate ( ETX ) , CPT-11 and high dose Epirubicin ( EPI HD ) are recommended as new effective drugs . Response rates recently reported for the combination CT with the drugs mentioned above for NSCLC are from 30-65%, and with 8-42 weeks of MST. Induction or neoadjuvant therapies for advanced NSCLC, with 40-69% of RR, 25-29% of complete resection rate, 8-34% of CR and 17-45% of one year SR are reviewed. Eight random studies comparing MST between CT with C-DDP and best supportive care for NSCLC are statistically significant. (2) RT for Stage III NSCLC with 2 year and 5 year survivals of 20 and 5% respectively. Although such outcome is hardly acceptable, RT sensitizer, modified RT techniques and chemoradiotherapy (CRT) are imperative to improve the effect of RT in advanced NSCLC. Clinical literature suggest that CRT is better than RT, though without marked difference. Further studies and sufficient follow-up are necessary to judge the efficacy in terms of long-term survival and toxic reaction. (3) Biological therapy: gene therapy of NSCLC is still in the experimental and developmental stage. Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported. Instillation of BRM such as IL-2 or alpha-IFN into the pleura after drainage of cancerous effusion has been reported as the most effective for those whose RR is of 80-90% and the clinical response time is fairly long. Hematological cytokine as a protective adjuvant therapy against CT/RT toxicity makes high dose of CT possible and raises the response and patient tolerance. In multimodality therapy, it plays an important role to reduce post CT infection and septicemia."}
{"sentence": "One group was given enalapril ( EN ) 50 mg/l dissolved in the drinking water ; the second received lovastatin ( L ) 15 mg/kg given daily by gavage ; the third received both agents ; the fourth was left untreated , and the final group received no puromycin and served as the control group .", "spans": [{"span_id": 0, "text": "enalapril", "start": 20, "end": 29, "token_start": 4, "token_end": 4}, {"span_id": 1, "text": "lovastatin", "start": 99, "end": 109, "token_start": 19, "token_end": 19}, {"span_id": 2, "text": "puromycin", "start": 246, "end": 255, "token_start": 48, "token_end": 48}], "rels": [{"class": "COMB", "spans": [0, 1]}], "paragraph": "The combination of lovastatin and enalapril in a model of progressive renal disease. puromycin-induced nephrotic syndrome is an animal model of progressive renal disease. Both angiotensin converting enzyme inhibitors and lipid-lowering agents have been used to preserve renal structure and function in this model, although neither completely prevents progression. We tested the hypothesis that the combination of the two agents would be more protective than either alone. Rats were divided into five groups; all were uninephrectomized. Four groups were given puromycin at a dose of 10 mg/100 g body weight (BW) with additional doses of 4 mg/100 g BW given intraperitoneally at 4, 5, and 6 weeks thereafter. One group was given enalapril ( EN ) 50 mg/l dissolved in the drinking water ; the second received lovastatin ( L ) 15 mg/kg given daily by gavage ; the third received both agents ; the fourth was left untreated , and the final group received no puromycin and served as the control group . Eight weeks after the initial dose of puromycin, glomerular filtration rate (GFR), as inulin clearance, and protein excretion were determined and blood was collected for cholesterol and triglycerides. Blood pressure was not different between any of the groups. At the end of the study period, serum cholesterol [mean +/- SD, 252 +/- 185 mg/dl (L), 135 +/- 101 mg/dl (L + EN)] and triglycerides (239 +/- 200, 148 +/- 158 mg/dl) were significantly lower (P < 0.001) in the lovastatin-treated groups than in the untreated puromycin group (535 +/- 255 mg/dl and 579 +/- 561 mg/dl, cholesterol and triglyceride, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)"}
{"sentence": "Using the Killing-curve method , we tested the in vitro bactericidal activity of fosfomycin alone or in combination with vancomycin or teicoplanin at a concentration of 8 microg/mL , that is easily achievable in serum at standard dosing regimens , against seven methicillin-resistant Staphylococcus aureus strains , isolated from patients with well documented device-associated infections unresponsive to or relapsing after glycopeptide therapy .", "spans": [{"span_id": 0, "text": "fosfomycin", "start": 81, "end": 91, "token_start": 13, "token_end": 13}, {"span_id": 1, "text": "vancomycin", "start": 121, "end": 131, "token_start": 19, "token_end": 19}, {"span_id": 2, "text": "teicoplanin", "start": 135, "end": 146, "token_start": 21, "token_end": 21}], "rels": [{"class": "COMB", "spans": [0, 1]}, {"class": "COMB", "spans": [0, 2]}], "paragraph": "In vitro activity of fosfomycin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy. fosfomycin is a molecule that inhibits the early stage of peptidoglycan synthesis and shows a broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria. Using the Killing-curve method , we tested the in vitro bactericidal activity of fosfomycin alone or in combination with vancomycin or teicoplanin at a concentration of 8 microg/mL , that is easily achievable in serum at standard dosing regimens , against seven methicillin-resistant Staphylococcus aureus strains , isolated from patients with well documented device-associated infections unresponsive to or relapsing after glycopeptide therapy . MICs of vancomycin ranged from 1 to 4 microg/mL, MICs of teicoplanin from 2 to 8 microg/mL; MICs of fosfomycin were 8 microg/mL for two strains and >128 microg/mL for the remaining strains. The seven strains proved tolerant when tested for vancomycin and teicoplanin used alone at 2x MIC concentration. fosfomycin was bactericidal (reduction of 2 log of the inoculum) only against the two susceptible strains. In all cases both vancomycin and teicoplanin in combination with fosfomycin developed bactericidal synergism already at a concentration of 1x MIC. If these results are confirmed by in vivo experiments, the combination of fosfomycin with glycopeptides might be useful for treating device-associated infections, and in preventing the phenomenon of increasing MICs for glycopeptides."}
{"sentence": "Combination therapy with mitomycin , tamoxifen , and UFT proved to be an effective postoperative chemoendocrine therapy for stage II , ER-positive breast cancer .", "spans": [{"span_id": 0, "text": "mitomycin", "start": 25, "end": 34, "token_start": 3, "token_end": 3}, {"span_id": 1, "text": "tamoxifen", "start": 37, "end": 46, "token_start": 5, "token_end": 5}, {"span_id": 2, "text": "UFT", "start": 53, "end": 56, "token_start": 8, "token_end": 8}], "rels": [{"class": "POS", "spans": [0, 1, 2]}], "paragraph": "UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group. A trial was designed to examine the combination of UFT and mitomycin (Mutamycin) plus tamoxifen (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive primary breast cancer. mitomycin was administered intravenously at 13 mg/m2 on the day of surgery. Patients judged to be ER-positive were randomly allocated to either group A, which received oral tamoxifen 20 mg/day 14 days after surgery for 2 years, or group B, receiving oral UFT 400 mg/day plus tamoxifen 20 mg/day. A total of 219 patients were enrolled in group A, of which 213 (97.3%) were determined to be eligible; 225 patients enrolled in group B and 223 (99.1%) were eligible. The 5-year survival rates were 93.0% for group A and 95.4% for group B, with no significant difference between groups. The 5-year relapse-free survival rates were 83.1% for group A and 90.7% for group B, a significant advantage (P = .020) for the UFT plus tamoxifen group. Combination therapy with mitomycin , tamoxifen , and UFT proved to be an effective postoperative chemoendocrine therapy for stage II , ER-positive breast cancer ."}
{"sentence": "The remaining 76 patients did not receive anti-thymocyte globulin but were given cyclosporine A and methotrexate or mycophenolate mofetil ( group 3 ) .", "spans": [{"span_id": 0, "text": "cyclosporine", "start": 81, "end": 93, "token_start": 12, "token_end": 12}, {"span_id": 1, "text": "methotrexate", "start": 100, "end": 112, "token_start": 15, "token_end": 15}, {"span_id": 2, "text": "mycophenolate", "start": 116, "end": 129, "token_start": 17, "token_end": 17}], "rels": [{"class": "COMB", "spans": [0, 1]}, {"class": "COMB", "spans": [0, 2]}], "paragraph": "The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. The impact of the intensity of graft-versus-host-disease immunoprophylaxis on transplantation outcomes in patients undergoing transplantation following reduced-intensity conditioning is unclear. This study addresses this issue in 228 adult patients above 50 years of age with acute myeloid leukemia in first complete remission given peripheral blood stem cells from HLA-identical siblings after fludarabine and 2 days of intravenous busulfan reduced-intensity conditioning. A total of 152 patients received anti-thymocyte globulin, either in combination with cyclosporine A in 86 patients (group 1), or with cyclosporine A and mycophenolate mofetil or short course methotrexate in 66 patients (group 2). The remaining 76 patients did not receive anti-thymocyte globulin but were given cyclosporine A and methotrexate or mycophenolate mofetil ( group 3 ) . Incidences of grade II-IV acute graft-versus-host-disease were comparable in the three groups (16.5%, 29.5% and 19.5% in groups 1, 2 and 3, respectively, P=0.15). In multivariate analysis, the absence of anti-thymocyte globulin was the only factor associated with a higher risk of chronic graft-versus-host-disease (P=0.005), while the use of triple immunosuppression (group 3) was associated with an increased risk of relapse (P=0.003). In comparison to anti-thymocyte globulin and cyclosporine A alone, the other two strategies of graft-versus-host-disease prophylaxis were associated with reduced leukemia-free survival and overall survival (P=0.001 for each parameter), independently of the dose of anti-thymocyte globulin. These data suggest that fine tuning of the intensity of this prophylaxis can affect the outcome of transplantation and that anti-thymocyte globulin and cyclosporine A alone should be the preferred combination with the fludarabine-busulfan reduced-intensity conditioning regimen and sibling donors. "}
{"sentence": "Propranolol significantly decreased the maximum plasma concentration ( Cmax ) and area under the plasma concentration-time curve ( AUC ) of lacidipine ( by 38 % and 42 % , respectively ) whereas lacidipine significantly increased the Cmax and AUC of propranolol ( by 35 % and 26 % , respectively ) ; neither the time to maximum plasma concentration ( tmax ) nor the terminal half-life ( t 1/2 ) were affected .", "spans": [{"span_id": 0, "text": "Propranolol", "start": 0, "end": 11, "token_start": 0, "token_end": 0}, {"span_id": 1, "text": "propranolol", "start": 250, "end": 261, "token_start": 41, "token_end": 41}, {"span_id": 2, "text": "lacidipine", "start": 140, "end": 150, "token_start": 21, "token_end": 21}], "rels": [{"class": "COMB", "spans": [0, 2]}], "paragraph": "The pharmacokinetic and pharmacodynamic interaction between lacidipine and propranolol in healthy volunteers. The pharmacokinetic and pharmacodynamic profiles of lacidipine, a 1,4-dihydropyridine calcium antagonist, and the beta-adrenoceptor blocker propranolol were determined alone and in combination in 24 healthy male volunteers. One group (I) of 12 subjects received a single oral dose of 4 mg lacidipine on two separate occasions, which was taken together with a single oral dose of either 160 mg propranolol or placebo; a second group (II) of 12 subjects received propranolol on two occasions, taken with either lacidipine or placebo. Propranolol significantly decreased the maximum plasma concentration ( Cmax ) and area under the plasma concentration-time curve ( AUC ) of lacidipine ( by 38 % and 42 % , respectively ) whereas lacidipine significantly increased the Cmax and AUC of propranolol ( by 35 % and 26 % , respectively ) ; neither the time to maximum plasma concentration ( tmax ) nor the terminal half-life ( t 1/2 ) were affected . With regard to the pharmacodynamics, in Group I, there was a greater reduction in supine systolic blood pressure (6 mm Hg) and diastolic blood pressure (4 mm Hg) compared to the reduction produced by lacidipine alone, and pulse rate was approximately 5 beats/min less. In Group II, a significantly greater reduction (6 mm Hg) in supine systolic blood pressure compared to the reduction produced by propranolol alone occurred, but there was no marked difference in supine diastolic blood pressure and pulse rate. In conclusion, a modest pharmacokinetic and pharmacodynamic interaction is evident and should be evaluated further in patients with hypertension."}
{"sentence": "For antibiotic treatment , mice were administered a mixture of ciprofloxacin and metronidazole or vancomycin .", "spans": [{"span_id": 0, "text": "ciprofloxacin", "start": 63, "end": 76, "token_start": 10, "token_end": 10}, {"span_id": 1, "text": "metronidazole", "start": 81, "end": 94, "token_start": 12, "token_end": 12}, {"span_id": 2, "text": "vancomycin", "start": 98, "end": 108, "token_start": 14, "token_end": 14}], "rels": [{"class": "COMB", "spans": [0, 1]}, {"class": "COMB", "spans": [0, 2]}], "paragraph": "Dietary soyasaponin attenuates 2,4-dinitrofluorobenzene-induced contact hypersensitivity via gut microbiota in mice. Soyasaponins (SSs) are abundant in soybeans and display inhibitory activity against contact hypersensitivity (CHS), which is often used as a mouse model for allergic contact dermatitis (ACD); however, their therapeutic mechanisms remain unknown. Here, we attempted to clarify the role of gut microbiota in the inhibition of CHS by dietary soyasaponins. For antibiotic treatment , mice were administered a mixture of ciprofloxacin and metronidazole or vancomycin . These antibiotics and SSs were given to mice via drinking water 3-weeks prior to CHS induction with 2,4-dinitrofluorobenzene, and the mice were analysed for ear swelling, tissue oedema, infiltration of Gr-1-positive immune cells, the composition of faecal microbiota and regulatory T (T"}
{"sentence": "The patient received chemotherapy comprising vincristine , actinomycin D , doxorubicin , cisplatin , and cyclophosphamide .", "spans": [{"span_id": 0, "text": "vincristine", "start": 45, "end": 56, "token_start": 5, "token_end": 5}, {"span_id": 1, "text": "doxorubicin", "start": 75, "end": 86, "token_start": 10, "token_end": 10}, {"span_id": 2, "text": "cyclophosphamide", "start": 105, "end": 121, "token_start": 15, "token_end": 15}, {"span_id": 3, "text": "actinomycin", "start": 59, "end": 70, "token_start": 7, "token_end": 7}, {"span_id": 4, "text": "cisplatin", "start": 89, "end": 98, "token_start": 12, "token_end": 12}], "rels": [{"class": "COMB", "spans": [0, 1, 2, 3, 4]}], "paragraph": "Autologous peripheral blood stem cell transplantation in a patient with relapsed pleuropulmonary blastoma. Pleuropulmonary blastoma (PPB) is a rare and aggressive primary intrathoracic neoplasma of children. The prognosis is extremely poor with frequent metastasis to the brain and bone. We present a 4-year-old girl with a tumor mass in the right hemithorax initially diagnosed as pneumoniae. Tumor resection was performed and the histologic report indicated the diagnosis of PPB. The patient received chemotherapy comprising vincristine , actinomycin D , doxorubicin , cisplatin , and cyclophosphamide . Irradiation was performed with total 45 Gy at the right lower pulmonary lobe. She relapsed 29 months later at the pleura between the right middle and lower pulmonary lobe. Tumor resection and total 45 Gy of irradiation were performed again. High-dose chemotherapy comprising cisplatin, adriamycin, and cyclophosphamide was performed followed by autologous peripheral blood stem cell transplantation (PBSCT). The patient achieved complete hematologic recovery. Thirty-one months after PBSCT, no signs of relapse have been observed. Although it might be that the patient could have been cured with second surgery alone or by the surgery and subsequent chemotherapy, high-dose chemotherapy and PBSCT should be considered for the treatment of relapsed PPB."}
{"sentence": "It was found that the increase in acoustic startle responses observed with ethanol or nicotine was attenuated by haloperidol .", "spans": [{"span_id": 0, "text": "nicotine", "start": 86, "end": 94, "token_start": 14, "token_end": 14}, {"span_id": 1, "text": "haloperidol", "start": 113, "end": 124, "token_start": 18, "token_end": 18}], "rels": [], "paragraph": "Nicotine and ethanol enhancements of acoustic startle reflex are mediated in part by dopamine in C57BL/6J mice. nicotine has been shown to have additive as well as antagonistic effects on behavior stimulated by ethanol. Here, we examine the effects of nicotine, ethanol, and the coadministration of each drug on acoustic startle responding in C57BL/6J mice. Mice were tested at a range of decibel levels (80-115 dB, 5 dB increments), with administration of 0.031, 0.062, 0.125, and 0.25 mg/kg nicotine or 0.5, 1.0, 1.5, and 2.0 g/kg ethanol. nicotine and ethanol each caused an increase in the acoustic startle response at the highest and lowest doses tested, respectively. mecamylamine, a nicotinic receptor antagonist, administered in combination with nicotine or ethanol attenuated these increases in acoustic startle responding. nicotine and ethanol, administered together, did not produce greater enhancement of startle than when administered alone. haloperidol (1 mg/kg) was administered in combination with nicotine or ethanol to investigate if dopamine modulated nicotine or ethanol enhancement of acoustic startle. It was found that the increase in acoustic startle responses observed with ethanol or nicotine was attenuated by haloperidol . Thus, ethanol or nicotine may enhance the acoustic startle reflex through a common dopaminergic mechanism."}
{"sentence": "The use of tacrolimus ( 88 % vs 77 % , P=.02 ) and cytolytic therapy ( 81 % vs 46 % , P < .0001 ) was likewise greater among patients who received ganciclovir prophylaxis .", "spans": [{"span_id": 0, "text": "tacrolimus", "start": 11, "end": 21, "token_start": 3, "token_end": 3}, {"span_id": 1, "text": "ganciclovir", "start": 147, "end": 158, "token_start": 34, "token_end": 34}], "rels": [], "paragraph": "Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients. Cytomegalovirus (CMV) infection is associated with reduced graft and patient survival among renal transplant recipients. The purpose of this study was to examine the effect of routine prophylaxis with 12 weeks of oral ganciclovir on the incidence of CMV infection in a center that predominantly uses antibody induction together with tacrolimus/mycophenolate mofetil-based maintenance immunosuppressive therapy. The control group consisted of a historical patient cohort transplanted immediately prior to the use of oral ganciclovir prophylaxis. The use of tacrolimus ( 88 % vs 77 % , P=.02 ) and cytolytic therapy ( 81 % vs 46 % , P < .0001 ) was likewise greater among patients who received ganciclovir prophylaxis . CMV infection occurred in 20 (9%) patients in the ganciclovir era and 4 (3%) patients in the preganciclovir era (P=.003). The mean time to CMV infection was longer in patients who received ganciclovir prophylaxis than in patients in the preganciclovir era (23.4 +/- 10.9 weeks vs 9.8 +/- 5.6 weeks, P=.03). We conclude that 12 weeks of ganciclovir prophylaxis delays but does not prevent CMV infection from occurring in renal transplant recipients. These results suggest that with the use of 12 weeks of ganciclovir prophylaxis, vigilance for CMV infection is needed well beyond 24 weeks posttransplant."}
{"sentence": "Because gemcitabine has been considered a standard treatment for advanced pancreatic cancer for the past decade , several randomized trials have tested the combination of gemcitabine plus a second agent , including platinum based agents , topoisomerase inhibitors , taxanes , bevacizumab and cetuximab , as biologically \" targeted \" agents .", "spans": [{"span_id": 0, "text": "gemcitabine", "start": 8, "end": 19, "token_start": 1, "token_end": 1}, {"span_id": 1, "text": "gemcitabine", "start": 171, "end": 182, "token_start": 25, "token_end": 25}, {"span_id": 2, "text": "bevacizumab", "start": 276, "end": 287, "token_start": 41, "token_end": 41}, {"span_id": 3, "text": "cetuximab", "start": 292, "end": 301, "token_start": 43, "token_end": 43}], "rels": [{"class": "COMB", "spans": [1, 2]}, {"class": "COMB", "spans": [1, 3]}], "paragraph": "First-line treatment for advanced pancreatic cancer. Highlights from the \"2011 ASCO Gastrointestinal Cancers Symposium\". San Francisco, CA, USA. January 20-22, 2011. Pancreatic adenocarcinoma remains a treatment-refractory cancer. Although pancreatic adenocarcinoma is only the 10th most common cause of new cancer in the United States, it is the fourth most common cause of cancer-related death. Most cases are not suitable for resection and a majority is metastatic at presentation. gemcitabine, with or without erlotinib, has been the standard chemotherapy in this setting but the benefit is only modest. Because gemcitabine has been considered a standard treatment for advanced pancreatic cancer for the past decade , several randomized trials have tested the combination of gemcitabine plus a second agent , including platinum based agents , topoisomerase inhibitors , taxanes , bevacizumab and cetuximab , as biologically \" targeted \" agents . At large this approach has not been successful and novel strategies are clearly needed. In this article, the authors summarizes the data from the 2011 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including: Abstract #175 (review of survival data in a large cohort); Abstract #286 (rapid change in prescriber patterns after the suggestion of benefit of a new regimen, FOLFIRINOX); Abstracts #238, #277, #304, and #315 (phase II trials looking at combinations that utilized EGFR blockade); Abstracts #221, #266, and #284 (phase I/II trials including VEGF blockade, anticoagulation, and traditional Chinese medicines)."}
{"sentence": "Melatonin , an indoleamine hormone secreted by the pineal gland , plays pleiotropic roles in the cardiovascular system ; however , the effect of melatonin on vulnerable plaque rupture and its underlying mechanisms remains unknown .", "spans": [{"span_id": 0, "text": "Melatonin", "start": 0, "end": 9, "token_start": 0, "token_end": 0}, {"span_id": 1, "text": "melatonin", "start": 145, "end": 154, "token_start": 24, "token_end": 24}], "rels": [], "paragraph": "Melatonin stabilizes rupture-prone vulnerable plaques via regulating macrophage polarization in a nuclear circadian receptor ROR\u03b1-dependent manner. Rupture of vulnerable plaques is the main trigger of acute cardio-cerebral vascular events, but mechanisms responsible for transforming a stable atherosclerotic into a vulnerable plaque remain largely unknown. Melatonin , an indoleamine hormone secreted by the pineal gland , plays pleiotropic roles in the cardiovascular system ; however , the effect of melatonin on vulnerable plaque rupture and its underlying mechanisms remains unknown . Here, we generated a rupture-prone vulnerable carotid plaque model induced by endogenous renovascular hypertension combined with low shear stress in hypercholesterolemic ApoE"}
{"sentence": "Gemcitabine and recently FOLFIRINOX ( 5-flourouracil , leucovorin , oxaliplatin and irinotecan ) have provided some limited survival advantage in advanced pancreatic cancer .", "spans": [{"span_id": 0, "text": "Gemcitabine", "start": 0, "end": 11, "token_start": 0, "token_end": 0}, {"span_id": 1, "text": "leucovorin", "start": 55, "end": 65, "token_start": 7, "token_end": 7}, {"span_id": 2, "text": "oxaliplatin", "start": 68, "end": 79, "token_start": 9, "token_end": 9}, {"span_id": 3, "text": "irinotecan", "start": 84, "end": 94, "token_start": 11, "token_end": 11}], "rels": [], "paragraph": "Immunotherapy updates in pancreatic cancer: are we there yet? Pancreatic cancer is a lethal disease and remains one of the most resistant cancers to traditional therapies. Historically, chemotherapy or radiotherapy did not provide meaningful survival benefit in advanced pancreatic cancer. Gemcitabine and recently FOLFIRINOX ( 5-flourouracil , leucovorin , oxaliplatin and irinotecan ) have provided some limited survival advantage in advanced pancreatic cancer . Targeted agents in combination with gemcitabine had not shown significant improvement in the survival. Current therapies for pancreatic cancer have their limitations; thus, we are in dire need of newer treatment options. Immunotherapy in pancreatic cancer works by recruiting and activating T cells that recognize tumor-specific antigens which is a different mechanism compared with chemotherapy and radiotherapy. Preclinical models have shown that immunotherapy and targeted therapies like vascular endothelial growth factor and epidermal growth factor inhibitors work synergistically. Hence, new immunotherapy and targeted therapies represent a viable option for pancreatic cancer. In this article, we review the vaccine therapy for pancreatic cancer."}
{"sentence": "No synergism was found against Pneumococci and Meningococci but also no antagonism of the lower MIC and MBC values seen with ampicillin and penicillin G. The combination of chloramphenicol with either penicillin or ampicillin constitutes a clinically successful therapeutic regimen which is now also proven by in vitro investigations .", "spans": [{"span_id": 0, "text": "ampicillin", "start": 125, "end": 135, "token_start": 21, "token_end": 21}, {"span_id": 1, "text": "chloramphenicol", "start": 173, "end": 188, "token_start": 28, "token_end": 28}, {"span_id": 2, "text": "ampicillin", "start": 215, "end": 225, "token_start": 33, "token_end": 33}, {"span_id": 3, "text": "penicillin", "start": 140, "end": 150, "token_start": 23, "token_end": 23}, {"span_id": 4, "text": "penicillin", "start": 201, "end": 211, "token_start": 31, "token_end": 31}], "rels": [{"class": "COMB", "spans": [0, 3]}, {"class": "POS", "spans": [1, 4]}, {"class": "POS", "spans": [1, 2]}], "paragraph": "[Bactericidal action of chloramphenicol and synergism with beta-lactam antibiotics]. Excellent clinical results were observed with the combination therapy of chloramphenicol with beta-lactam-antibiotics in the treatment of purulent meningitis. This came as a surprise as bacteriostatic antibiotics like chloramphenicol are commonly thought to antagonize the bactericidal action of penicillin or ampicillin. We reevaluated the mode of action of chloramphenicol against the three most common meningeal pathogens after the newborn period. chloramphenicol was found to be bactericidal against H. influenzae, Streptococcus pneumoniae and Neisseria meningitidis at clinically achievable levels in the CSF. In addition chloramphenicol showed synergistic action with ampicillin against H. influenzae which can possess clinical relevance particularly with the high inoculum of 10(7) organisms/ml which is frequently seen in bacterial meningitis. No synergism was found against Pneumococci and Meningococci but also no antagonism of the lower MIC and MBC values seen with ampicillin and penicillin G. The combination of chloramphenicol with either penicillin or ampicillin constitutes a clinically successful therapeutic regimen which is now also proven by in vitro investigations ."}
{"sentence": "Similarly , nifedipine , nitroglycerin and hydralazine should not to be considered first-line therapies in the management of hypertensive crises because these agents are associated with significant toxicities and/or adverse effects .", "spans": [{"span_id": 0, "text": "nifedipine", "start": 12, "end": 22, "token_start": 2, "token_end": 2}, {"span_id": 1, "text": "hydralazine", "start": 43, "end": 54, "token_start": 6, "token_end": 6}], "rels": [], "paragraph": "Treatment of acute severe hypertension: current and newer agents. Approximately 72 million people in the US experience hypertension. Worldwide, hypertension may affect as many as 1 billion people and be responsible for approximately 7.1 million deaths per year. It is estimated that approximately 1% of patients with hypertension will, at some point, develop a hypertensive crisis. Hypertensive crises are further defined as either hypertensive emergencies or urgencies, depending on the degree of blood pressure elevation and presence of end-organ damage. Immediate reduction in blood pressure is required only in patients with acute end-organ damage (i.e. hypertensive emergency) and requires treatment with a titratable, short-acting, intravenous antihypertensive agent, while severe hypertension without acute end-organ damage (i.e. hypertensive urgency) is usually treated with oral antihypertensive agents. The primary goal of intervention in a hypertensive crisis is to safely reduce blood pressure. The appropriate therapeutic approach of each patient will depend on their clinical presentation. Patients with hypertensive emergencies are best treated in an intensive care unit with titratable, intravenous, hypotensive agents. Rapid-acting intravenous antihypertensive agents are available, including labetalol, esmolol, fenoldopam, nicardipine and sodium nitroprusside. Newer agents, such as clevidipine and fenoldopam, may hold considerable advantages to other available agents in the management of hypertensive crises. Sodium nitroprusside is an extremely toxic drug and its use in the treatment of hypertensive emergencies should be avoided. Similarly , nifedipine , nitroglycerin and hydralazine should not to be considered first-line therapies in the management of hypertensive crises because these agents are associated with significant toxicities and/or adverse effects ."}
{"sentence": "Bendamustine is effective both with rituximab and as a monotherapy in rituximab-refractory patients .", "spans": [{"span_id": 0, "text": "Bendamustine", "start": 0, "end": 12, "token_start": 0, "token_end": 0}, {"span_id": 1, "text": "rituximab", "start": 36, "end": 45, "token_start": 5, "token_end": 5}], "rels": [{"class": "POS", "spans": [0, 1]}], "paragraph": "Bendamustine in chronic lymphocytic leukemia and refractory lymphoma. bendamustine is a water-soluble, bifunctional chemotherapeutic agent with characteristics of both an alkylator and a purine analog. bendamustine combined with rituximab in vitro shows synergistic effects against various leukemia and lymphoma cell lines. Clinical trials supporting these results show that bendamustine plus rituximab is highly effective in relapsed and refractory patients with indolent lymphoma. The results have been found in rituximab-naive, rituximab-pretreated, and rituximab-refractory patients with excellent response rates and toxicity profiles. Bendamustine is effective both with rituximab and as a monotherapy in rituximab-refractory patients . Interim results from a phase III, randomized trial comparing bendamustine and rituximab to a standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and rituximab regimen suggest that combination bendamustine and rituximab may provide a viable alternative for treatment of many indolent lymphomas."}
{"sentence": "In this work , the combination of membrane bioreactor ( MBR ) and electro-oxidation ( EO ) process was studied for the treatment of a synthetic hospital wastewater fortified with four pharmaceutical pollutants namely carbamazepine ( CBZ ) , ibuprofen ( IBU ) , estradiol ( E-E ) at a concentration of 10 \u03bcg L", "spans": [{"span_id": 0, "text": "carbamazepine", "start": 217, "end": 230, "token_start": 34, "token_end": 34}, {"span_id": 1, "text": "ibuprofen", "start": 241, "end": 250, "token_start": 39, "token_end": 39}], "rels": [], "paragraph": "Synthetic hospital wastewater treatment by coupling submerged membrane bioreactor and electrochemical advanced oxidation process: Kinetic study and toxicity assessment. In this work, the combination of membrane bioreactor (MBR) and electro-oxidation (EO) process was studied for the treatment of a synthetic hospital wastewater fortified with four pharmaceutical pollutants namely carbamazepine (CBZ), ibuprofen (IBU), estradiol (E-E) at a concentration of 10\u00a0\u03bcg\u00a0 In this work , the combination of membrane bioreactor ( MBR ) and electro-oxidation ( EO ) process was studied for the treatment of a synthetic hospital wastewater fortified with four pharmaceutical pollutants namely carbamazepine ( CBZ ) , ibuprofen ( IBU ) , estradiol ( E-E ) at a concentration of 10 \u03bcg Lg\u00a0L"}
